Index

Page references followed by f denote figures. Page references followed by t denote tables.

AAP (American Academy of Pediatrics), 77–78
AAT (auscultated acceleration test), 182
Abdomen enlargement, as probable sign of pregnancy, 128–129
Abdominal exam, postpartum, 433–434
Abdominal pain in pregnancy, 398–399
abdominal trauma, 399
appendicitis, 399
cholelithiasis, 399
normal causes, 398
OLD CAARTS mnemonic, 398
Abdominal strengthening exercises, 429
Abdominal trauma, 399
Abdominal wound infection, 445
ABM (Academy of Breastfeeding Medicine), 253
ABO incompatibility, 45
Abortion
aspiration, 144
defined, 409
dilation and evacuation (D & E) procedure, 144
habitual, 341
medical, 144
spontaneous (see Spontaneous pregnancy loss)
Abscess, breast, 507–508
Absolute risk, 149, 153
Abuse Prevention and Treatment Act, 252
Academy of Breastfeeding Medicine (ABM), 253, 493
Acceptance of pregnancy, 297–301
ACEI (angiotensin converting enzyme inhibitors), 232
Acetaminophen
after stillbirth, 413
asthma association, 196
for back or pelvic girdle pain, 196
for carpal tunnel syndrome, 198
for headaches, 575, 576
incidence of use by pregnant women, 224
Acetylcholinesterase (AChE), 168
ACFP (American College of Family Physicians), 77
ACHOIS (Australian Carbohydrate Intolerance Study in Pregnant Women), 388
Acidemia
defined, 176
fetal, 361
prediction of, 182, 184, 187
Acidosis, 176
Acne, 580
ACNM. See American College of Nurse-Midwives
ACOG. See American College of Obstetricians and Gynecologists
Acquired seizure disorder, 570
Acrosome reaction, 19–20
ACTH. See Adrenocorticotropic hormone
Active labor
ambulation in early labor, 330
case study, 331
coping strategies and comfort measures for early labor, 330
data collection, 327–328
defined, 325
determining, 327
timing of admission to birth setting, 326
Active seizure disorder, 570–571, 573
Active transport, 19, 23, 24
Acupressure
for nausea and vomiting of pregnancy, 218
for nausea relief, 209f
Acupuncture
for headaches, 576f
for stimulation of milk production, 509
Acute cystitis, 536–538
Acute pustular psoriasis of pregnancy.
See Impetigo herpetiformis (IH)
Acyclovir, for herpes simplex virus (HSV), 611–612, 612f
Adaptation
defined, 291
psychosocial in pregnancy, 291–309
Addiction
ASAM definition, 240
counseling for, 241
terminology, 239–240
Adequacy of Prenatal Care Utilization (APNCU) Index, 79
Adequate intake, 99
ADH (antidiuretic hormone), 46
Adipose tissue, 551–552
Admission to birth setting, timing of, 326
Adolescents
cognitive development of, 314–315
intimate partner violence, 265
nutrition, 116–117
assessment, 116
counseling, 116–117
recommended intakes of nutrients, 116
strategies for dietary change, 116–117
postnatal care, 436–437
prenatal health education, 314–315
preventing STIs, 617
Adoption
counseling, 143–144
positive language for discussing, 144
Adrenal gland, function changes during pregnancy, 47
Adrenarche, 5, 13
Adrenocorticotropic hormone (ACTH), 46–47
chorionic, 25, 26f
Adult education principles, 315
Adverse drug reaction, 223
AFAFP (amniotic principles alpha-fetoprotein), 168
Affective state, 291
AFI. See Amniotic fluid index
AFP (alpha-fetoprotein), 160, 162, 168
Afterbirth pain, 430
Afterpains, 419–420
AFV. See Amniotic fluid volume
AGA (appropriate for gestational age), 358
Antibiotics
for gastroenteritis, 545
for group B Streptococcus (GBS), 592
for mastitis, 507
for pylonephritis, 541
for upper respiratory infection, 522
for urinary tract infection, 539–540, 540t
for uterine infection, 445
for wound infections, 445
Antibodies
defined, 608
in sexually transmitted infections, 610–612
Anticipatory guidance, 317
defined, 193
for discomforts of pregnancy, 194
for onset of labor, 327
for pregnant women who are substance dependent, 249
for women who will give birth while incarcerated, 264
in multifetal pregnancy, 403
Antidepressants, 571, 572
Antidiuretic hormone (ADH), 46
Anti-D immunoglobulin (RhoGAM), 483
Antidiuretic hormones, 46
Antihistamines
for atopic dermatitis, 581
for intrahepatic cholestasis of pregnancy (ICP), 586
for pemphigoid gestationis (PG), 584
for prurigo of pregnancy, 582
for pruritic urticarial papules and plaques of pregnancy (PUPP), 583
for upper respiratory infection, 522, 522t
Antimicrobial compounds, in human milk, 482
Antineoplastic agents, teratogenicity of, 232t
Antioxidants, for preeclampsia prevention, 383
Antithyroid antibodies, 562
Antithyroid drugs, teratogenicity of, 232t
Anxiety, defined, 291
Anxiety disorders
defined, 441
postpartum, 448–457
assessment and screening, 452
generalized anxiety disorder (GAD), 450t, 451, 626–627
management, 452–457, 453t–456t
obsessive-compulsive disorder, 450t, 451
panic disorder, 450t, 451
post-traumatic stress disorder (PTSD), 450t, 451–452
signs and symptoms, 450t
prevalence of, 448
APNCU (Adequacy of Prenatal Care Utilization) Index, 79
Apocrine sweat glands, 41
Apoptosis, 19–20
Appendicitis, 40, 399
Appendicitis, 40, 399
Arnold-Chiari malformation (ACM), 92
Atopic dermatitis, 580–581
Attenuated infantile spasms syndrome (AIS), 126
Atomic bomb, 26
Atresia, 5, 11
Attachment
defined, 291
maternal, 292–301
partner, 302–305, 302t
sibling, 301–302
Attributable risk, 149, 153
AUDIT C screening tool, 245
Augmentin (amoxicillin-clavulanate) for upper respiratory infection, 522
for urinary tract infection, 540t
Aura, 570, 574
Auscultated acceleration test (AAT), 182
Auscultation of the fetal heart, 85, 132, 132f
Australian Carbohydrate Intolerance Study in Pregnant Women (ACHOIS), 388
Autosomal recessive conduction defects, 167
Avidity testing, 589, 591, 601
AWHONN (Association of Women's Health, Obstetric and Neonatal Nurses), 264
Azithromycin for chlamydia, 609
for gastroenteritis, 545
for gonorrhea, 610
Baby-Friendly Hospital Initiative (BFHI), 480
Baby shower, 299
Background risk, 223, 228
Back pain, 194–196
assessment, 195
causes and symptoms, 194–195
incidence of, 194
relief and preventative measures, 195–196, 195t
Baclofen, 243
Bacterial infection
gastroenteritis, 544–545
group B Streptococcus (GBS), 592–593
sexually transmitted infections (STIs), 609–610
urinary tract infection (UTI), 536–541, 539t–540t
Bacterial vaginosis (BV), 614–616
Amstel criteria, 614
as ecological disorder, 615
Nugent scoring system, 614–615, 615t
practice points for, 616
preterm birth and, 370
prevalence of, 614
testing and treatment, 614–615
Bacteriuria. See also Urinary tract infection (UTI)
asymptomatic, 370, 537, 542
defined, 536
Ballantyne, John, 73, 74
Bariatric surgery, 555
Barker, David, 102
Barker hypothesis, 102
Barrier methods of contraception, 472–474
Bartholin gland, 8, 8f
Basal body temperature (BBT)
change for gestational age estimation, 138
defined, 125
for pregnancy diagnosis, 131
Basal metabolic rate (BMR), 41, 103
“Bath salts,” 244
Bayley Mental Development Index,
“Bath salts,” 244
Bartholin gland, 8, 8
Barrier methods of contraception,
Barker hypothesis, 102
Basal body temperature (BBT)
change for gestational age estimation, 138
defined, 125
for pregnancy diagnosis, 131
Basal metabolic rate (BMR), 41, 103
“Bath salts,” 244
Bayley Mental Development Index,
Billings method, of fertility awareness,
Biliary sludge, 546
Bichloroacetic acid, for human
Bipolar disorder, 622t, 625–626, 626t
classification, 622t, 625
management of, 626
risks associated with, 625
signs and symptoms, 625–626, 626t
Birth defects. See also Teratology
baseline risk of, 160
etiology of, 228, 228f
Birth experience, review of, 426
Birth fear, 153
Birth order, 302
Birth plan, defined, 312
Birth weight
average, 30
classifications, 358
macrosomia, 361–362
Bishop score, 397, 406, 406t
Bisphenol A (BPA)
Biparietal diameter, gestational age
estimation by, 140
Biparietal diameter, gestational age
defined, 352, 397
interpretation and management of
score, 186t
intrauterine growth restriction and,
361
key points of, 187
Manning scoring criteria, 185t
modified, 187, 187f, 352, 361, 397,
406t
in post-term pregnancy, 406t
in pre eclampsia management, 380
Vintzileos scoring criteria, 185t
Biparietal diameter, gestational age
defined, 352, 397
interpretation and management of
score, 186t
intrauterine growth restriction and,
361
key points of, 187
Manning scoring criteria, 185t
modified, 187, 187f, 352, 361, 397,
406t
in post-term pregnancy, 406t
in pre eclampsia management, 380
Vintzileos scoring criteria, 185t
Biparietal diameter, gestational age
defined, 352, 397
interpretation and management of
score, 186t
intrauterine growth restriction and,
361
key points of, 187
Manning scoring criteria, 185t
modified, 187, 187f, 352, 361, 397,
406t
in post-term pregnancy, 406t
in pre eclampsia management, 380
Vintzileos scoring criteria, 185t
Birefringent
Bisphenol A (BPA)
estrogen and, 590
exposure to, 655–656
imprinting and, 73–74
pregnancy and, 655
risk factors for, 555
screening for, 656, 656t
toxicology of, 590
Bisphenol A (BPA), 165, 166
Bleeding
Benign causes of, 336, 336t
case studies, 349–350
delayed postpartum, 441, 445–446
differential diagnosis, 345
ectopic pregnancy, 341–343
diagnosis, 342
incidence, 342
management of, 342–343, 343t
maternal death and, 342
recurrence risk, 343
risk factors for, 342, 342t
signs and symptoms, 342, 342t
evaluation, 336–337
diagnostic testing, 337
laboratory evaluation, 337, 337t
physical exam, 336–337
problem-focused history, 336
during first half of pregnancy,
335–336
gestational trophoblastic disease
(GTD), 343–344
diagnosis and management, 344
incidence of, 344
potential problems, 344
presentation, 344
recurrence risk, 344
risk factors for, 344t
types, 343t
gums, 196
implantation, 19, 22
inherited disorders, 531
leiomomas, 337
malformation, 531
placental abruption, 346–348
defined, 335, 346
incidence of, 346
potential problems, 347
presentation, 347–348
risk factors for, 347t
types, 347, 347f
placenta previa, 345–346, 346f, 346t
differential diagnosis, 346
potential problems, 345–346
presentation, 346
risk factors for, 346t
types, 345, 346f
postpartum, 420
potential problems of unexplained
early, 341
prevalence of, 336
resources for women and their
families, 348
scope of practice considerations,
344–345, 345t, 348
during second half of pregnancy,
345
causes, 345–348
diagnosis and management, 348
family considerations, 348
scope of practice considerations,
348
spontaneous pregnancy loss, 337–341
classification of first-trimester loss,
338t
defined, 335, 338
diagnosis, 339
differential diagnosis, 338–339,
339t
family considerations, 340–341
follow-up care, 340
incidence of, 338
management, 339–340
expectant management, 339–340
medical, 340
surgical, 340
recurrent, 341
Index 635

risk factors for, 338, 339t
signs and symptoms, 339t
subchorionic hemorrhage or hematoma, 337
terminology, 335
thrombocytopenia, 531
Bloating, 398t
Blood glucose monitoring, in gestational diabetes (GDM) management, 391–392
Blood pressure. See also Hypertensive disorders
maternal alterations during pregnancy, 37–38
supine hypotensive syndrome, 37–38
Blood supply to cervix, 9
uterine to cervix, 9
Bloom syndrome, genetic screening for, 167
Blues, postpartum, 423, 425–426, 441, 449
BMI. See Body mass index
BMR (basal metabolic rate), 41, 103
Body hair changes during pregnancy, 213
Body image
clothing as extension of, 306
defined, 291
postpartum, 306
in pregnancy, 305–306
social comparison, 305
Body mass index (BMI), 99
defined, 549
insulin resistance and, 551
obesity and, 549–556, 550t
Bonding, 47, 426–427. See also Attachment
Borg rating of perceived exertion (RPE), 277, 277f
Botanicals, 224–225, 234
defined, 223
for stimulation of milk production, 509–510
Bottle-feeding, 428
Bowby, John, 293
BPA. See Bisphenol A
BPP. See Biophysical profile
Bradley method, 75, 313
Braxton Hicks contractions, 130, 325, 331, 398t
Brazelton, T. Berry, 294
Breast
abscess, 507–508
anatomy, 482–483, 482f
changes as presumptive signs of pregnancy, 128
development, 482
engorgement, 499, 506–507
exam, postpartum, 433
physiology of lactation and breastfeeding, 482–483
skin changes, 212
Breast cancer genes (BRCA1 and BRCA2), 61
Breastfeeding, 478–495
anatomy and physiology of, 482–483, 482f
asthma exacerbations, management of, 520, 520f
basics
latch, 487–488, 488f
position, 484, 487, 487f
care of breastfeeding mother, 491–494
alcohol use, 493
contraception, 433, 492
employed nursing mothers, 493–494
illicit drug use, 493
medications, 493
nutrition, 429, 491–492
smoking, 492–493
case study, 495
checklist of maternal knowledge and skills acquired before discharge, 484
contraception and, 433, 492
contraindications to, 479
defense agents in human milk, 492
discharge instructions for, 484, 485
estrogen-containing contraceptives and, 490
flavor learning, 102
intake, assessing, 490–491
lactational amenorrhea method (LAM) of contraception,
462–463, 472
maternal nutrition/diet and, 429, 491–492
oral aversion, 499–500
sleepy baby, 500–501
slow weight gain, 501–502, 501t–502t
sore nipples, 503–506, 505t
resources for health-care providers, 511
resources for women and their families, 511
terminology, 499
Breast tenderness, 196–197
assessment, 197
causes and symptoms, 196–197
relief and preventative measures, 197
Breath, shortness of, 211–212
Breckinridge, Mary, 73
Broad ligament, 9f
Bronchitis, 522
BTC (behind-the-counter) drug, 223
Budesonide, for asthma, 519
Bulb of the vestibule, 8
Bulbocavernosus muscle, 8
Bulbospongious muscle, 8f
Bulimia nervosa, 118–119
Buprenorphine
breastfeeding and, 254t
drug-drug interactions and, 248
for opioid dependence, 250–251
Buprenorphine/naloxone combination therapy, 250
Bupropion, 246, 253
black box warning, 455t
for depression, 457
FDA approved indications, 455t
side effects, 455t
Buspirone
FDA approved indications, 455t
side effects, 455t
BV. See Bacterial vaginosis
B vitamin deficiency, in vegetarian/vegan diet, 118
Contraception, 462–476
Continuous labor support, 325, 330
Constipation, 40, 198–199, 199t
Consent, 169.
resources for women and health-care
postpartum, 432–433, 462–476
methods, 465–474
medical eligibility criteria (MEC),
tier two methods, 465
tier three methods, 465
tier one methods, 465
sterilization, 466–467
male sterilization (vasectomy),
466–467
permanent, 466–467
progestin-only contraceptives, 462,
470–472
spermicides, 473–474
sterilization, 462, 466–467
tier one methods, 465t, 466–469
tier three methods, 465t, 472–474
tier two methods, 465t, 469–472
vaginal diaphragms, 473
withdrawal, 474
postpartum, 432–433, 462–476
considerations in method selection,
463–465
interpregnancy intervals, 462
lactational amenorrhea method
(LAM), 462–463
return to fertility after childbirth,
463
“Rule of Threes,” 463
when to start, 463
resources for women and health-care
providers, 476
STI prevention and, 617–618
terminology, 462
Contraceptive sponges, 473
Contraceptive Technology (Hatcher),
475
Contractions, 325–331
assessment of, 328
Braxton Hicks, 130, 325, 331, 398t
defined, 325
determining onset of labor, 325–326
false labor and, 326–327
postpartum, 419–420
Contraction stress test (CST), 183, 406t
Control, fear of loss in labor, 300
Controlled substance, 223, 225, 226
Controlled substance, 223, 225, 226t
Coping, defined, 291
Copper IUD, 467, 468, 475
Cordocentesis, 168
Corneal edema, 45
Corna, 5, 11
Corona radiata, 15, 19, 20
Coronary heart disease, low birth weight
linked to, 102–103
Corpus albicans, 15
Corpus luteum
formation of, 15
involution of, 15, 16
life span of, 14
progesterone secretion by, 16–17
Corticosteroids
for asthma, 519, 519t, 520f
for atopic dermatitis, 581
for hyperemesis gravidarum, 401
for impetigo herpetiformis (IH),
585
nasal for upper respiratory infection,
522, 522r
for pemphigoid gestationis (PG),
584
for preeclampsia management, 380
for prurigo of pregnancy, 582
for pruritic folliculitis of pregnancy,
583
for pruritic urticarial papules and
plaques of pregnancy (PUPP),
583
teratogenicity of, 232t
Corticotropin-releasing hormone (CRH),
25, 47
Cortisol, 47
in prenatal depression, 623
striae gravidarum color and, 42
Costovertebral angle tenderness (CVAT),
434
Costs, risk assessment and, 152–153
Cough suppressants, for upper
respiratory infection, 522, 522r
Coumarin, teratogenicity of, 232t
Counseling
adoption, 143–144
antenatal fetal testing, 188
geneic
perspective on, 171–172
pretest counseling, 170
referrals to genetic counselor, 169
on parvovirus B19, 597
preconception, 57–61
conception process, 60
diet, 57, 59
environmental exposure to toxins,
60–61
exercise, 59
infections, 60
in pregestational diabetes, 567
preparation for pregnancy and
childbirth, 60
substance use and abuse, 59–60
supplementation, 59
vaccinations, 61, 62t
weight, 59
pregnancy diagnosis, 140–145
adoption counseling, 143–144
after negative pregnancy test, 141
after positive pregnancy test, 141
delivery of test results, 140–141
ethics and standards for
reproductive options counseling, 142
evidence-based information about
pregnancy options, 143
pregnancy termination, 144–145
steps in pregnancy options
counseling, 143
for unintended pregnancy, 141–143
prenatal nutrition, 57, 59, 114, 116
in adolescent pregnancy, 116–117
in multifetal pregnancy, 403, 403f
on sexuality in pregnancy, 285–286
substance abuse, 248
on varicella infection, 603
on working during pregnancy, 287–288
Court order of protection, 266
Couvade, 303
Couvade syndrome, 303
Couvadera uteris, 335, 347
CRAFFT screening tool, 245
C-reactive protein, increase in pregnancy,
25, 47
Critical periods in human development,
228–229, 230f
Cromolyn sodium, for upper respiratory
infection, 522, 522r
Crown-rump length, gestational age
estimation by, 140
CRS (congenital rubella syndrome), 227,
598–599
Cytotrophoblast, 19, 21–22, 27
Cytomegalovirus (CMV), 590–591
Cytokines, 34, 43–44

Defensive care practices, by obstetrician

Deep vein thrombosis (DVT), 37, 448f, 531–532
defined, 441
in obese women, 556
postpartum, 447, 556
risk factors for venous thrombosis, 445f
as sequelae to IV drug use, 241
symptoms, 447

Defensive care practices, by obstetrician gynecologists, 152

Dehydration
in hyperemesis gravidarum, 401
in nausea and vomiting of pregnancy, 207

Dehydroepiandrosterone sulfate (DHEA-S), 25, 26f, 47

Delayed lactogenesis II, 499

Delayed postpartum hemorrhage, 441, 445–446

Dendritic cells, 43–44

Dependence, opioid, 250

Depot medroxyprogesterone acetate (DMPA), 470–471, 492

Depression. See also Bipolar disorder case study, 458
comorbid with substance use, 241
postpartum, 435, 449–450
assessment and screening, 452
differential diagnosis, 450

Edinburgh Postnatal Depression Scale (EPDS), 435, 452
management, 450, 452–457, 453–456
prevalence of, 448–449
risk factors for, 449
signs and symptoms, 449, 450f
thyroid function studies and, 448
during pregnancy, 621–625, 622f, 624f
case study, 628
contributing factors, 621, 623
incidence of, 621
management of, 623–625
outcomes of untreated, 623, 624f
pharmaceutical considerations in treating, 624f
problems of, 623, 624f
screening for, 623
with pregnancy loss, 341
screening tools, 435, 452
signs and symptoms of, 622f, 623
sleeplessness and, 287

Dermatological disorders, 580–588
abbreviations for skin disorders, 581f
atopic dermatitis, 580–581
case study, 580

DHEA-S (dehydroepiandrosterone sulfate), 25, 26, 26f

Developmental phase, pregnancy as, 292–293

Dick-Read, Grantly, 73, 75, 313

Dickinson’s sign, 125, 130

Diabetes mellitus classifications, 566, 566f
etiology, 566, 566f

gestational diabetes (GDM)
decrease risk with exercise, 275
incidence of, 566
preconception care for, 64
pregestational, 566–567

Dermoplast, for perineal discomfort, 431

DES (diethylstilbestrol), 74, 232f

Designer drugs, 244

Desonide, for pruritic folliculitis of pregnancy, 582

Development
breast, 482
chorionic and amniotic membranes, 22–23
cleavage, 20, 21f
embryo, 27–29
folding, 28, 31f
gastrulation, 27, 27f

neurulation, 28
notochord formation, 28, 29f
organogenesis, 28–29
primitive streak, 27–28, 27f

fetus, 29–30
implantation, 21
placenta functions, 23–25, 24f, 26f
structure, 21–22
umbilical cord, 23

Developmental phase, pregnancy as, 292–293

DHA (docosahexaenoic acid), 104, 106f, 118

DHEA-S (dehydroepiandrosterone sulfate), 25, 26, 47

DIA (dimeric inhibin A), in genetic screening, 163

Diarrhea, in gastroenteritis, 544–545

Diaphragms, vaginal, 473

Diastasis, 423, 434

DIC. See Disseminated intravascular coagulation

Dickinson’s sign, 125, 130

Dick-Read, Grantly, 73, 75, 313
Diet. See also Nutrition
for gestational diabetes (GDM)
management, 390–391, 391f
for headache control, 575
postpartum, 429
preconception counseling, 57, 59
Dietary counseling, in iron-deficiency
anemia, 527–529, 528f
Dietary reference intake (DRI), 99, 100
Discomforts of pregnancy, 193–220
Discharge instructions for breastfeeding,
Dilatation and evacuation (D & E)
procedure, 144
Dimeric inhibin A (DIA), in genetic
Dilation, 325–328
Diethylstilbestrol (DES), 74, 232
Dietary counseling, in iron-deficiency
anemia, 527–529, 528f
Dietary screening, 163
Diphenhydramine, 329, 581
Diploid, 19–20
Disabilities, preconception care for
women with, 65
Discharge instructions for breastfeeding,
484, 485f
Discomforts of pregnancy, 193–220
back pain and pelvic girdle pain,
194–196
assessment, 195
ting symptoms, 194–195
relief and preventative measures,
195–196, 195f
bleeding gums, 196
assessment, 196
ting symptoms, 196
relief and preventative measures, 196
breast tenderness, 196–197
assessment, 197
ting symptoms, 196–197
relief and preventative measures, 197
carpal tunnel syndrome (CTS),
197–198
assessment, 197–198
ting symptoms, 197
relief and preventative measures, 198
cervical pain, 198
constipation, 198–199, 199f
assessment, 198
ting symptoms, 198
relief and preventative measures,
198–198, 199f
dizziness/syncope, 199–200
assessment, 199
ting symptoms, 199
relief and preventative measures,
199–200
edema, 200
assessment, 200
ting symptoms, 200
relief and preventative measures,
200
emotional changes, 200–201
assessment, 201
ting symptoms, 200
relief and preventative measures,
201
Epistaxis, 206–207
fatigue, 201
assessment, 201
ting symptoms, 201
relief and preventative measures, 201
flailence, 201–202
assessment, 201–202
ting symptoms, 201
relief and preventative measures,
202
headache, 202–203
assessment, 202
ting symptoms, 202
relief and preventative measures,
203–204
heart palpitations, 204
assessment, 204
ting symptoms, 204
relief and preventative measures,
204–205
hernia, 205–206
assessment, 205
ting symptoms, 205
relief and preventative measures,
205–206, 205f
hemorrhoids, 204
assessment, 204
ting symptoms, 204
relief and preventative measures,
204
increased warmth and perspiration,
204–205
leg cramps, 205–206
assessment, 205
ting symptoms, 205
relief and preventative measures,
205–206, 205f
leukorrhea, 205
assessment, 205
ting symptoms, 205
relief and preventative measures,
205
nasal congestion, 206
assessment, 206
ting symptoms, 206
relief and preventative measures,
206
nausea and vomiting of pregnancy
(NVP), 207–209, 208f–209f, 209f
assessment, 207, 208f
case study, 218
ting symptoms, 207
relief and preventative measures,
207–208, 208f–209f, 209f
in obese women, 555
overview signs and symptoms, 193–194
ptyalism, 209–210
assessment, 210
ting symptoms, 209
relief and preventative measures, 210
related resources for health-care providers
and women and their families, 220
restless leg syndrome (RLS), 210–211
assessment, 210
ting symptoms, 210
relief and preventative measures,
210–211
round ligament pain, 211, 211f
assessment, 211
ting symptoms, 211
relief and preventative measures, 211
shortness of breath, 211–212
assessment, 211–212
ting symptoms, 211
relief and preventative measures,
212
skin changes, 212–214
assessment, 213
hair and nail changes, 213
hyperpigmentation, 212–213, 212f
relief and preventative measures,
213–214
striae gravidarum, 212–213, 213f
vascular changes, 213
sleep disturbances, 214–215
assessment, 214
case study, 219
ting symptoms, 214
relief and preventative measures,
214–215
supine hypotension syndrome (SHS),
215
assessment, 215
ting symptoms, 215
relief and preventative measures, 215
terminology, 193
urinary frequency, 215
assessment, 215
ting symptoms, 215
relief and preventative measures, 215
urinary incontinence, 216
assessment, 216
ting symptoms, 216
relief and preventative measures, 216
varicosities, 216–218
leg, 216–217
vulvar, 217–218, 217f
visual changes, 219–220
assessment, 219
ting symptoms, 219
relief and preventative measures, 220
Discrimination in the workplace, 287
Discriminatory drug screening policies,
240
Disseminated intravascular coagulation (DIC)
defined, 375
in preeclampsia, 377
Diuresis, 431
Dizygotic twins, 397, 401
Dizziness/syncope, 199–200
assessment, 199
causes and symptoms, 199
incidence of, 199
relief and preventative measures, 199–200
DMDA (depot medroxyprogesterone acetate), 470–471, 492
Docosahexaenoic acid (DHA), 104, 106, 118
Domperidone, for stimulation of milk production, 509
Doppler flow studies, intrauterine growth restriction and, 361
Doppler ultrasound, for auscultation of fetal heart, 85, 132, 217
Doppler velocimetry
antenatal fetal testing, 187–188
defined, 352
Doula, postpartum, 425
Down syndrome. See Trisomy 21
Doxepin
FDA approved indications, 454r
side effects, 454r
DRI. See Dietary reference intake
Drug Addiction Treatment Act of 2000, 250
Drug-drug interaction, for substance exposed pregnancies, 248
Drug Enforcement Administration (DEA), 225, 250
Drug resistance, defined, 223
Duloxetine
FDA approved indications, 455r
side effects, 455r
Dumpling syndrome, 549
DVT. See Deep vein thrombosis
Dysthymic disorder, 622r
Dystocia, 325, 327
Dysuria, 536, 538
Early labor. See Labor onset
ambulation in, 330
coping strategies and comfort measures for, 330
defined, 325
determining active labor, 327
plan of care, 328–329
self-care, 329
sleep and rest in, 329–330
timing of admission to birth setting, 326
Early pregnancy loss, defined, 409
Eating disorders, 118–119
Eating disorders not otherwise specified (EDNOS), 118–119
Eccrine sweat glands, 41
Eclampsia, 376–377
laboratory manifestations of, 381f
postpartum, 441, 446–447
Ectoderm, 19, 21–22, 27–28, 27f
Ectopic pregnancy, 341–343
defined, 335
diagnosis, 342
incidence, 342
management of, 342–343, 343t
maternal death and, 342
recurrence risk, 343
risk factors for, 342, 342t
signs and symptoms, 342, 342t
Ectropion, 5
Edema, 200
Edema of pregnancy. See Prurigo of pregnancy
Eden, 580–581
Eczema of pregnancy. See Prurigo of pregnancy
Ectropion, 5
Edema, 200
assessment, 200
causes and symptoms, 200
in preeclampsia, 379
relief and preventative measures, 200
Edinburgh Postnatal Depression Scale (EPDS), 88, 452, 623
Education. See Health education
Edwards syndrome.
Endometrial cycle, 15–17
Endocrine-disrupting chemicals (EDCs), 274, 283
EDD (estimated date of delivery or estimated due date), 125–126
Edema, 200
assessment, 200
causes and symptoms, 200
in preeclampsia, 379
relief and preventative measures, 200
Edinburgh Postnatal Depression Scale (EPDS), 88, 452, 623
Education. See Health education
Edwards syndrome. See Trisomy 18
Effacement, 325, 327–328
EFM (electronic fetal monitor), 181
EFW. See Estimated fetal weight
Eicosapentaenoic acid (EPA), 104, 106, 118
fish consumption guidelines, 104–105, 105r
Elastic stocking, 217
Electroacupuncture, for milk production stimulation, 509
Electronic fetal monitor (EFM), 181
ELISA. See Enzyme-linked immunosorbent assay
Embryo development, 27–29
folding, 28, 31f
gastrulation, 27, 27f
neurulation, 28
notochord formation, 28, 29f
organogenesis, 28–29
primitive streak, 27–28, 27f
Emergency contraception, 462, 474–475
Emollients
for atopic dermatitis, 581
for pemphigoid gestationis (PG), 584
for prurigo of pregnancy, 582
for pruritic urticarial papules and plaques of pregnancy (PUPP), 583
Emotion
defined, 291, 301
effects of events/influences, 301
Emotional changes, 200–201
assessment, 201
causes and symptoms, 200
relief and preventative measures, 201
Emotional cushioning, 409, 413–414
Employment, of nursing mothers, 493–494
Endocervical canal, 5, 9–10
Endocrine disorders, 560–568
case study, 568
pregestational diabetes, 566–567
adverse pregnancy outcomes and, 567
classifications, 566
glycemic control, 567
perinatal risks of, 567
preconception counseling, 567
resources for women and health-care providers, 567
terminology, 560
thyroid disorders, 560–566
causes and expected laboratory findings, 561r
diagnosing, 561–562
hyperthyroidism, 561r, 564–565
hypothyroidism, 561r, 562–564
postpartum thyroiditis (PPT), 561r, 565–566
signs and symptoms, 562
thyroid physiology in pregnancy, 560–561, 561f
Endocrine-disrupting chemicals (EDCs), 274, 283
Endocrine pregnancy test, 125, 131–132
Endocrine system
maternal alterations during pregnancy, 46–47
adrenal function changes, 47
anatomical changes, 46
pituitary function changes, 46–47, 46f
thyroid function changes, 47
physiological alterations during postnatal period, 421
Endoderm, 19, 21–22, 27–28, 27f
Endometrial cycle, 15–17, 17f
Endometritis, 441, 443. See also Uterine infection
Endometrium, 5, 9f
anatomy, 10
decidual reaction, 22
postpartum changes, 420
Endorphins, exercise and, 429
Engorgement, breast, 499, 506–507
Environmental and Occupational Health
History Profile, 280, 281f
Environmental exposures, 279–284
assessment of, 280, 281f
to endocrine-disrupting chemicals
(EDCs), 283
Environmental and Occupational
Health History Profile, 280, 281f
to metals and metalloids, 280, 282
to organic solvents, 282
to pesticides, 283
preconception counseling on, 60–61
preconception risk assessment and
screening, 56, 57f
reducing, 283–284
Resources on pregnancy and
environmental exposure for
women, 288
Resources on pregnancy and
environmental exposure for
health-care providers, 288
Resource on work during pregnancy
for women, 288
Enzyme-linked immunosorbent assay
(ELISA)
defined, 589
for hepatitis C, 596
for parvovirus B19, 597
for varicella zoster, 603
EP (eczema of pregnancy). See Prurigo
of pregnancy (PP)
EPA. See Eicosapentaenoic acid
EPDS (Edinburgh Postnatal Depression
Scale), 88
Epigastric pain, 546
Epilepsy. See Seizure disorders
Epistaxis, 206–207
Epstein anomaly, 621
Epulis, 34, 40
Erb’s palsy, 397
Ergonovine, for delayed postpartum
hemorrhage, 446
Erythema infectiosum, 597
Erythrocyte sedimentation rate, increase
in pregnancy, 44
Erythromycin, for chlamydia, 609
Erythropoiesis, 35
Eschar, 423
Escherichia coli
antibiotic resistance, 539
in urinary tract infections, 537, 539
Escitalopram
FDA approved indications, 453f
side effects, 453f
motivating women, 276–277, 276f
in obese women, 554
physiological changes of pregnancy
and, 274–275
“talk test,” 278
terminology, 274
transtheoretical stages of change
and, 276–277, 276f
warning signs to stop, 279
prenatal health promotion and
education, 93–94
reasons to discontinue or decrease,
93–94
Exercise intensity, 277, 277f
Exophthalmos, 560, 564
Expectation, 291
Expected date of birth (EDB). See
Estimated date of birth
Expectorants, for upper respiratory
infection, 522, 522f
Expert Panel on the Content of Prenatal
Care, 75–79, 81, 84–85, 92
Expressing breast milk, 493–494
External anal sphincter, 8, 8f
External genitalia, anatomy of, 6–8, 7f
External os, 9f
External urethral orifice, 6f–8f
Extraembryonic somatic mesoderm, 19,
22
Eye changes during pregnancy, 45
Facilitated transport/facilitated diffusion,
19, 23, 24f
Fallopian tubes, 10–11
False labor, 326–327
False negative rate, 160
False positive rate, 160
Famiclovir, for herpes simplex virus
(HSV), 611–612, 612f
Familial dysautonomia, genetic screening
for, 87f, 166f, 167
Family
defined, 291
genetic risk evaluation, 161
in poverty, 263
Family adaptation, postnatal care
assessment of, 426–428
Family history, 84
Family Medical Leave Act (FMLA), 94
FAMs (fertility awareness-based
methods), 462, 474
Fanconi’s anemia, genetic screening for,
167
Fantasy, in maternal role taking, 296
FAS (fetal alcohol syndrome), 242
FASD (fetal alcohol spectrum disorder),
59, 92, 242
Fas/FasL, 34, 43
Fasting blood glucose (FBG), in
gestational diabetes (GDM)
management, 391–392
Fetal assessment for substance exposed pregnancies, 249
Fetal death, 409. See also Pregnancy loss; Stillbirth
conditions related to increased risk of, 177, 178r
Fetal fibronectin (fFN) testing, 368
Fetal growth and development, prenatal teaching regarding, 294
Fetal growth disorders, 358–362. See also specific disorders
case study, 363
determination of growth disorders, 358–359
fetal weight percentiles throughout gestation, 359f
intrauterine growth restriction, 359–361
macrosomia, 361–362
resources for health-care providers, 363
resources for women and their families, 363
terminology, 352–353
Fetal growth restriction (FGR), 100
Fetal heart activity defined, 125
identification of, 132, 132f
Fetal heart rate (FHR), 132
accelerations, 180–183
baseline, 176
monitoring, 180–183, 181f
variability, 176
Fetal heart sounds defined, 125
maternal obesity and assessment of, 553
timing of hearing, 132
Fetal movement, detection of, 132–133, 134f
Fetal movement count (FMC), 178–180, 180f
education on, 179
factors influencing maternal perception of fetal movement, 179
key points on fetal movement, 180
in post-term pregnancy, 406r
techniques for, 179
Fetal/neonatal withdrawal, opioid, 249–252
Fetal origins of disease hypothesis, 102–103
Fetal well-being, assessment of, 176–190
antenatal fetal testing
amniotic fluid volume (AFV) assessment, 183, 184r
biophysical profile (BPP), 183–187
contraction stress test, 183
Doppler velocimetry, 187–188
fetal heart rate (FHR) monitoring, 180–183, 181f
fetal movement counts (FMCs), 178–180, 180f
methods, 178–188
nonstress test, 180–183
oxytocin challenge test (OCT), 183
physiological principles and indications for, 177
case study, 190
conditions related to increased risk of fetal death, 177, 178r
cultural, personal, and family considerations, 188–189
education and counseling, 188
health disparities and vulnerable populations, 189
legal and liability issues, 189–190
overview, 176–177
scope of practice considerations, 177–178
terminology, 176
Fetoscope, 125, 132, 132f
Fetotoxicity, 227
Fetus development, 29–30
FEV1, 517
Fever, puerperal, 443
Feverfew, for headache, 574
fFN (fetal fibronectin) testing, 368
FGR (fetal growth restriction), 100
Fiber, 99
for constipation, 199, 199r
for hemorrhoids, 204
Fibrinogen, 36
Fibrinolysis, 34, 36
Fibroadenomas, 193
Fibroids. See Uterine fibroids
Fifth disease, 597
Fimbriae, 5, 11
Financial security, 263
First-degree laceration, 423
First polar body, 5, 12, 12
Fish oil supplements, 104
5A's and 5 R's model of smoking cessation, 91, 92t, 246, 247t
Flat nipples, 499, 503, 504r
Flatulence, 201–202
assessment, 201–202
causes and symptoms, 201
relief and preventative measures, 202
Flavor learning, prenatal, 524
Flavonoids, associated with, 524
Fluid retention in pregnancy, 39
Fluoxetine
drug-drug interactions and, 248
FDA approved indications, 453r
side effects, 453r
Index
Gestational age
defined, 125
genetic screening and, 161
Gestational age assessment, 133–140
devices used to calculate, 136–137
early, 126
methods of estimating, 137–140
basal body temperature change, 138
fundal height measurements, 138–139, 139f
known date of conception, 138
last menstrual period (LMP), 137–138
ultrasound, 139–140
resources for women and their families, 145
terminology, 125, 133, 136
timing of events in gestation, 135–136
Gestational age wheels, 82
Gestational diabetes mellitus (GDM), 387–395
assessment after Roux-en-Y gastric bypass, 555
case study, 394
decrease risk with exercise, 275
defined, 387
fetal surveillance and timing of birth, 392–393
incidence of, 566
management of, 390–392
blood glucose monitoring, 391–392
dietary intervention, 390–391, 391f
exercise, 391
gliburide, 392
insulin therapy, 392
metformin, 392
oral medications, 392
nutrition in pregnancy and, 100, 103, 105
obesity and, 551–552
pathophysiology of, 387–388
postpartum follow-up, 393–394
potential problems of, 388, 388f
in preeclampsia, 378
prenatal screening and diagnosis of, 388–390, 389f
one-hour oral glucose tolerance testing, 389
screening high-risk women, 390
two-hour oral glucose tolerance testing, 389–390
resources for health-care providers, 395
resources for women and their families, 395
risk, perspective on, 394
risk factor classification for, 388f
risk factors for, 351
scope of practice issues, 394
terminology, 387
Gestational hypertension, 376
Gestational sac, 139–140
Gestational trophoblastic disease (GTD), 340, 343–344
diagnosis and management, 344
incidence of, 344
potential problems, 344
presentation, 344
recurrence risk, 349
risk factors for, 344f
types, 343f
Gestational weeks, 125, 133, 135f–136f, 136.
See also Gestational age assessment
GFR (glomerular filtration rate), 39
Ghrelin, 41
Gingival edema and hyperemia, 213
Gonadarche, 5
Gonadotropin-releasing hormone, 12
Gonadostat, 5
Gonadotropin-releasing hormone pulse generator (gonadostat), 12
Gonadarche, 13
Gonorrhea, 608, 609–610
pregnancy testing and treatment, 609–610
screening recommendations, 58f
Goodell’s sign, 125, 129
Governmental oversight of pharmaceutical agents, 225, 226f
Granulosa cells, 5, 14–15
Graves’ disease, 44, 560, 561f, 564
Gregg, Norman, 227
Gregg, Robin, 170
Grief, perinatal loss and, 341, 409–415
breaking the news, 410
care and management of women with stillbirth, 410–411, 411f
case study, 414
cultural considerations, 412
etiology of stillbirth, 410, 410f
grieving and emotional care after loss, 411–412, 412f
interconception care, 413
physical care after stillbirth, 413
postpartum follow-up, 413
resources for health-care providers, 415
resources for women and their families, 415
rights of parents when a baby dies, 412f
subsequent pregnancy care, 413–414
terminology, 409
Grief work, 296
Ground substance, 5, 10
Group B Streptococcus (GBS), 592–593
assessment, 592
incidence of infection, 592
management, 592–593
mortality rate in newborns, 592
potential problems, 592
prevalence in healthy women, 592
in urinary tract infections, 537, 539
Group prenatal care, 314
Growth charts, 491
Growth hormone
pituitary, 46
placental, 46
GTD. See Gestational trophoblastic disease
Gums, bleeding, 196
Habitual abortion, 341
Hair
changes during pregnancy, 213
maternal alterations during pregnancy, 42–43
Hamilton Anxiety Rating Scale (HAM-A), 627
Haploid, 19, 20
HAPO (Hyperglycemia and Adverse Pregnancy Outcomes), 389
Harm reduction approach to prenatal substance use, 240
Hart’s line, 5, 8
Hashimoto thyroiditis, 560, 561f, 562–563
HAV. See Hepatitis A virus
HBV. See Hepatitis B virus
hCG. See Human choric gonadotropin
HCV (hepatitis C virus), screening recommendations, 58f
Headache, 202–203, 573–577, 574f–576f
assessment, 202
causes and symptoms, 202
cluster, 570, 574, 576–577
dlary, 574
migraine, 570, 574–576
nonpharmacological management, 574–575, 576f
Headache (cont’d)
pharmacological treatment, 575–576
postpartum, 576
relief and preventative measures, 202–203
tension, 570, 574, 575r
triggers, 575
Head circumference, gestational age
estimation by, 140
Health disparity
defined, 261
postnatal care, 436–437
Health education, 312–323
antenatal fetal testing, 188
case study, 322
childbirth education
Bradley Method, 313
hospital-based classes, 313
hypnobirthing, 313
Lamaze, 313
prenatal visit approach to, 314
reading material, 314
reality television shows, 314
sources and quality of, 312–314
cultural considerations, 321
developmental considerations in prenatal education
adolescents, 314–315
adults, 315
documentation of teaching, 321
group prenatal care, 314
guidelines for prenatal education, 316
health disparities and vulnerable populations, 321
issues integral to prenatal education, 315–316
literacy and, 316
prenatal, 76, 88, 90–95
alcohol use, 92
exercise, 93–94
illicit drugs, 92–93
nutrition, 90–91, 91t
substance abuse, 91
throughout pregnancy, 94–95, 95t
tobacco use, 91–92, 92t
working and pregnancy, 94
Healthy People 2020 document, 316
Hearing, changes during pregnancy, 45
Heart
disease, signs and symptoms of pregnancy that mimic, 37t
maternal alterations during pregnancy, 37, 37t
Heartburn, 40, 203–204, 398t
assessment, 203
case study, 219
causes and symptoms, 203
incidence and prevalence of, 203
relief and preventative measures, 203–204
Heart palpitations, 204
assessment, 204
causes and symptoms, 204
relief and preventative measures, 204
Heart rate
fetal (see Fetal heart rate)
increased maternal during pregnancy, 37
Heavy lifting, 286
Heavy metals, exposure to, 280, 282
Hegar’s sign, s, 10, 125, 129, 129f
Helicobacter pylori, 207
HELLP syndrome, 382
laboratory manifestations of, 381f, 382
symptoms of, 382
Hematocrit, during normal pregnancy, 526t
Hematological disorders, 525–534
anemia, 525–529
diagnosis, 525–526
folic acid deficiency, 527t, 530
iron deficiency, 526–529, 527r–528t
physiological changes in pregnancy, 525–526
unexplained maternal, 530–531
vitamin B12 deficiency, 527t, 530
bleeding disorders, 531
case study, 534
coagulopathies, 531–534, 533t
hematological findings during normal pregnancy, 526t
hemoglobinopathies, 527t, 529–530
resource for women and their families, 534
resources for health-care providers, 534
terminology, 525
Hematologic system adaptations during pregnancy, 34–36, 35t
clotting factors, 36, 36t
folate requirements, 36
iron requirements, 35–36
plasma, 35
red blood cells, 35
white blood cells, 35
Hematoma, subchorionic, 337
Hematoma postpartum, 441, 446
Hematuria, 536, 538, 541
Heme iron. See Iron
Hemoglobin
A1C, 555, 567
findings during normal pregnancy, 526t
in hematology conditions, 527t
S, 525, 529
Hemoglobinopathies, 527t, 529–530
hemoglobin S, 525, 529
laboratory findings, 527t
thalassemia, 525, 527t, 529–530
Hemophilia A, 531
Hemophilia B, 531
Hemorrhage. See also Bleeding
decidual, 367
delayed postpartum, 441, 445–446
postpartum, 420
subchorionic, 337
Hemorrhoids, 204
assessment, 204
causes and symptoms, 204
postnatal care, 431
relief and preventative measures, 204
Hemostasis, 36
Heparin, for thromboprophylaxis, 532, 533t
Hepatitis A virus (HAV), 593–594
assessment, 593
incidence of, 593
management, 593–594
potential problems, 593
prevention, 594
risk factors, 593
Hepatitis B virus (HBV), 594–596
assessment, 594–595
antihapatitis B antibody (anti-HBc), 595
antihapatitis core antibody (anti-HBc), 595
HBe antigen, 595
hepatitis B surface antigen (HBsAg), 594
chronic infection, 594
management, 595
potential problems, 594
prevention, 595–596
screening recommendations, 58t
vaccination, 595
Hepatitis C virus (HBV), 596–597
assessment, 596
management, 596–597
potential problems, 596
prevalence of, 596
risk factors for, 596
Hepatitis C virus (HCV), screening recommendations, 58t
Herbals, 224
defined, 223
for depression, 625
for stimulation of milk production, 509–510
for mood and anxiety disorders, 457
Herd immunity, 589, 599
Herpes simplex virus (HSV), 608, 610–612, 611–612t
classification of genital, 611, 611t
congenital, 611
fetal infection, 611
neonatal, 611
pregnancy testing and treatment, 611–612, 612t
prevalence of, 610
recurrence during pregnancy, 611
screening recommendations, 58t
signs and symptoms, 611
Herpetiform, defined, 580
HG. See Hyperemesis gravidarum
Hirsutism, 193, 213
Histamine 2-receptor antagonists, 203
History
Environmental and Occupational
Health History Profile, 280, 281t
genetic risk evaluation, 161
nutritional, 112, 112t, 113f, 113t
preconception risk assessment and screening, 53
in preeclampsia diagnosis, 379
prenatal, 82–85
family, 84
infection, 84
initial visit, 82–84
nutritional, 84
pregnancy, 82, 84
psychosocial, 84
sexual, 84
subsequent visit, 85
sexual, 283
for vaginal bleeding, 336
HIV. See Human immunodeficiency virus
Homan’s sign, 423, 447
Homelessness, poverty and, 262–263
Homicide, 266
Hormones. See also specific hormones
hypothalamic-pituitary-ovarian axis, 13
levels in menstrual cycle, 17f
stimulating gonads, 14f
teratogenicity of, 233t
Housing, poverty and, 262–263
HPV. See Human papillomavirus
HSV. See Herpes simplex virus
Human chiorionic gonadotropin (hCG) beta-human chiorionic gonadotropin (β-hCG)
discriminatory levels for, 337t
dermatologic disorders, 342
ectopic pregnancy diagnosis, 342
gestational trophoblastic disease, 344
for pregnancy diagnosis, 131–132
serial, 337, 342, 344
fluctuations throughout pregnancy, 561f
functions of, 25, 26t
in genetic screening, 163, 164
hyperglycosylated hCG (h-hCG), in genetic screening, 163
placental production of, 24–25
thirst center stimulation by, 35
Human immunodeficiency virus (HIV)
breastfeeding and, 479
maternal-child transmission (MCT) of, 77
preconception care for, 64
preconception risk assessment and screening, 56
screening recommendations, 58t
Human papillomavirus (HPV), 612–613
pregnancy testing and treatment, 613
prevalence of, 612
vertical transmission rate, 613
Human placental lactogen, 25, 26
Humoral immunity, 44
Hunger, in breastfed infants, 500
Hydatidiform mole, 19, 25, 343–344, 343t
Hydantoin, 329
FDA approved indications, 455t
side effects, 455t
Hymen, 5–6, 6f
Hyperemesis gravidarum
Hyperglycemia and Adverse Pregnancy Outcomes (HAPO), 389
Hyperglycosylated human chorionic gonadotropin (h-hCG), in genetic screening, 163
Hyperparathyroidism, physiological, 46
Hyperpigmentation, 42, 212–213, 213f
Hyperlucemia, 34, 39, 419
Hypertension. See Hypertensive disorders
Hypertensive disorders, 375–385
case study, 385
chronic hypertension, 375–376, 376t
preeclampsia superimposed on, 376t, 377
classification and definitions of, 376t
decreased risk with exercise, 275
gestational hypertension, 376
maternal deaths from, 375
placental abruption and, 346
preeclampsia, 376–384
atypical presentation, 382–383, 383t
criteria for diagnosis of, 377t
diagnostic evaluation of, 379–380
HELLP syndrome, 382
incidence of, 377
interprofessional practice issues, 384
long-term sequelae of, 383–384
management of, 380–382
pathophysiology of, 377–378, 378f
potential problems due to, 378
prediction of, 383
prevention of, 383
risk factors for developing, 378–379
risk management issues in office setting, 384
superimposed on chronic hypertension, 376t, 377
prevalence of, 375
resources for health-care providers, 384
resources for women and their families, 384
terminology, 375
Hyperthyroidism, 561, 564–565
clinical presentation, 564
diagnosis, 564
Graves’ disease, 561t, 564
laboratory testing, 561t, 564
management, 564–565
maternal and fetal risks, 564
preconception care for, 64
scope of practice considerations, 565
signs and symptoms, 562
subclinical, 561t, 565
thyroid storm, 561t, 565
Hypertrophy, 419
Hypnobirthing, 313
Hypomania, 621, 622t, 625–626
Hyponatremia, in hyperemesis gravidarum, 400
Hypospadias, vegetarian diet and risk for, 117
Hypotension, in supine hypotension syndrome (SHS), 215
Hypothalamic-pituitary-ovarian axis, 13, 14f
Hypothalamus-pituitary-adrenal axis in mood and anxiety disorders, 449
premature activation and preterm birth, 366
Hypothalamic-pituitary-thyroid axis, 560, 561f
Hypothyroidism, 561, 562–564
clinical presentation, 562
complications of, 562
diagnosis, 562–563
Hashimoto thyroiditis, 560, 561f
laboratory testing, 561f, 562–563
management, 562–563
maternal and fetal risks, 562
overt, 562–563
preconception care in, 64, 563–564
subclinical, 561f, 563
Illusion of choice, 154
Immigrants, postnatal care for, 436–437
Immune globulin
hepatitis A virus (HAV), 593
hepatitis B virus (HBV), 595
varicella zoster, 603
Immune system, maternal alterations during pregnancy, 43–45
disorders related to, 44–45
fetus as allograft, 43–44
Immunity, herd, 589, 599
Immunization, prenatal, 88, 89f
Immunoglobulins
classes of, 44
defined, 589
Impetigo herpetiformis (IH), 582t, 585
Implantation
location of, 21
timing of, 21
Implantation bleeding, 19, 22
Implant contraception, 468–469
Incarceration, 264–265
Immunoglobulins
defined, 589
Inflammation, preterm birth and, 366–367
Inflammatory markers increased in pregnancy, 44
Influenza, 521
Interconception care
labor induction by, 405
after stillbirth, 413
ICP. See Intrahepatic cholestasis of pregnancy
Identification with motherhood role, 297
Idiopathic, defined, 352
Idiopathic seizure disorder, 570
Idiopathic thrombocytopenia purpura (ITP), 531
IgG antibodies, 589
IgM antibodies, 589
IH (impetigo herpetiformis), 582t, 585
Illus, 545
Illicit drug use
by breastfeeding mother, 493
preconception counseling on, 60
prenatal health promotion and education, 92–93
prevalence of, 239
uterine infection, 443–445,
444t–445t
resources for health-care providers, 604
resources for women, 604
risk with intrauterine contraception, 467–468
rubella, 597–599
STIs (Sexually transmitted infections) terminology, 589
toxoplasmosis, 599–602, 600f, 601t
transplacental, 24t
treating for preterm birth prevention, 370
varicella zoster virus (VZV), 602–603
wound, 445
Inferior hypogastric plexus, 8
Infection history, 84
Infections/infectious diseases, 589–604
Infection screening, 589
Infant feeding
bottle-feeding, 428
breastfeeding (see Breastfeeding)
formula-feeding, 428
postnatal care assessment, 428
Inferior hypogastric plexus, 8
In compartment, 169–170
Inhibin, 25, 26f
Inhibin A, in genetic screening, 163–164
Innate immune system, 43–44
INR (international normalized ratio), 532t
Insomnia. See Sleep disturbances
Inspiratory capacity, 517
Institute of Medicine (IOM), 79–80, 90, 91t
pregnancy weight gain recommendations, 107, 108t
Insufficient milk supply, 499, 508–510, 508t–509t
Insulin
for gestational diabetes (GDM), 392
as a growth hormone in pregnancy, 551
metabolic alterations during pregnancy, 41–42
for pregestational diabetes, 566
Insulin pump, 566
Insulin resistance, 41
body mass index (BMI) and, 551
defined, 387, 549
in gestational diabetes, 388
in preeclampsia, 378
Integrated screen, genetic, 163t, 164
Interoception care
after stillbirth, 413
defined, 51
Intercourse
labor induction by, 405
resumption of postpartum, 431–432
Interferon, for multiple sclerosis, 577
Internal anal sphincter, 8
Internal genitalia, anatomy of, 8–11, 9f
Internal os, 9f
Internal care, defined, 312
International Association of the Diabetes in Pregnancy Study Group (IADPSG), 389–390
International Board Certified Lactation Consultants (IBCLCs), 479
International normalized ratio (INR), 532t
Internet, as information source, 314
Interpregnancy interval, 462
Interpersonal violence, 265–266
Intimacy, resumption of sexual
Interval-type exercise, 277–278
Interval training, defined, 274
Interpregnancy interval, 462
Internet, as information source, 314
Interpersonal violence, 265–266
Intimacy, resumption of sexual
Interval-type exercise, 277–278
Interval training, defined, 274
Interpregnancy interval, 462
Internet, as information source, 314
Interpersonal violence, 265–266
Intimacy, resumption of sexual
Interval-type exercise, 277–278
Interval training, defined, 274
Interpregnancy interval, 462
Internet, as information source, 314
Interpersonal violence, 265–266
Intimacy, resumption of sexual
Interval-type exercise, 277–278
Interval training, defined, 274
Interpregnancy interval, 462
Internet, as information source, 314
Interpersonal violence, 265–266
Intimacy, resumption of sexual
Interval-type exercise, 277–278
Interval training, defined, 274
Interpregnancy interval, 462
Internal os, 9
symmetric, 360
defined, 352
asymmetric, 360
defined, 352
risk factors for development of, 361t
symmetric, 360
defined, 352
risk factors for development of, 361t
symmetric, 360
defined, 352
risk factors for development of, 361t
symmetric, 360
Intrahepatic cholestasis of pregnancy (ICP), 582t, 585–586
assessment, 586
collaboration, consultation, and referral, 586
defining characteristics of, 582t
differential diagnosis, 586
fetal outcomes of, 586
incidence of, 585
risk factors for, 585
treatment and management, 586
Intrauterine contraception (IUC), 462, 467–468
advantage of, 468
in breastfeeding women, 492
contraindications to use, 467–468
copper IUD, 467–468, 475
expulsion of device, 468
levonorgestrel IUD, 467
Intrauterine growth restriction (IUGR), 177, 359–361
assessment and management, 360–361
asymmetric, 360
defined, 352
risk factors for development of, 361t
symmetric, 360
Intrauterine infection. See Uterine infection
Introitus, 5, 8
Introitus, in maternal role taking, 296
Inverted nipples, 499, 503, 504t
in vitro fertilization, 305
Involution
assessment of, 433–434
defined, 423
Iodine, thyroid gland and, 47
Iris lesion, 580, 582
Iron
absorption of, 106, 527
food sources, 527–529, 528t
hematological findings during normal pregnancy, 526t
needs in pregnancy, 105–106, 106t
requirement changes during pregnancy, 35–36
in vegetarian/vegan diet, 118
Iron-deficiency anemia, 106, 526–529, 527–528t
dietary counseling, 527–529, 528t
iron supplements, 527, 527t
laboratory findings, 527t
Iron replacement therapy, for restless leg syndrome, 210
Iron supplements, 106, 527, 527t
Ischiocavernosus muscle, 8
Isolated cavernous muscle, 8f
Isotretinoin, 229, 233
Jaundice
defined, 544
intrahepatic cholestasis of pregnancy (ICP), 545–546
Katz-Rothman, Barbara, 171
Kava root, for mood and anxiety
Kegel exercises
for hemorrhoids, 204
for pelvic girdle pain, 195t
for perineal discomfort, 431
postpartum, 429
for urinary incontinence, 216
Kennell, Marshall, 293–294
Kessner Index, 79
Ketoconazole, 325, 328
Kidney adaptations during pregnancy, 38–39
anatomical changes, 39
renal function, 39
Kidney stones, 536, 541
Klaus, John, 293–294
Kleihauer-Betke test, 335, 348, 397
Known date of conception, for gestational age estimation, 138
K-Y Jelly, 432
Labeling women as high risk, 151
Labia
majora, 5–6, 6f–7f
minora, 5–6, 6f–7f
physiological alterations during postnatal period, 420
Labor
defined, 325
dystocia, 325, 327
in gestational diabetes (GDM), 393
induction (see Labor induction)
onset (see Labor onset)
preparation for, 299–300
preterm (see also Preterm birth)
diagnosis, 368
initial evaluation, 369
management of women with, 368–369
psychosocial adaptation to pregnancy, 299–300
Laboratory tests
preconception risk assessment and screening, 53
prenatal, 85–86, 86t, 87t
for substance exposed pregnancies, 248
for vaginal bleeding, 337, 337t
Labor induction
elective, 405–406
methods
caster oil, 405
stripping of the membranes, 397, 404–405
unprotected sexual intercourse, 405
for post-term pregnancies, 404–406
Labor onset
ambulation in early labor, 330
anticipatory guidance during prenatal period, 327
case study, 331
coping strategies and comfort measures for early labor, 330
data collection, 327–328
determining active labor, 327
determining onset of labor, 325–326
false labor, 326–327
plan of care, 328–329
self-care, 329
sleep and rest in early labor, 329–330
timing of admission to birth setting, 326
Labor-stimulating activities in post-term pregnancy, 404–405
Lactation, 478–495. See also
Breastfeeding
anatomy and physiology of, 482–483, 482f
asthma exacerbations, management of, 520, 520f
defense agents in human milk, 482
delayed, 489, 556
delayed exercise during, 491–492
dates resumption in lactating women, 432, 432f
milk production, 489, 490f
nutritional properties of human milk, 480–482
nutrition for nursing mothers, 491–492
in obese women, 556
terminology, 478
Lactational amenorrhea method (LAM), 462, 463, 472, 492
Lactation consultants, 479
Lactiferous ducts, 483
Lactobacilli, 5, 614–615, 615f
Lactogenesis I, 482
Lactogenesis II, 464, 482, 489
Lactose, 481
Lacunae, 19, 21
Ladun’s sign, 125, 129
LAM (lactational amenorrhea method), 462–463, 472, 492
Lamaze, Fernand, 73
Lamaze method, 75, 313
Lamotrigin, maternal and fetal effects of, 572f
Language as a reflection and construction of social realities, 299
Lanolin, use on nipples, 506
Languo, 19, 30
Laparoscopic gastric banding (LAP-BAND), 549, 555
LARC (long-acting reversible contraceptive methods), 462, 467–469
Large for gestational age (LGA), 352, 358, 361
defined, 387
in gestational diabetes (GDM), 393
maternal obesity and, 551–552
Last menstrual period (LMP), gestational age estimation, 137–138
Latch, in breastfeeding, 487–488, 488f
Late ovulation, 397, 404
Late preterm birth, 365–366, 366f
Late preterm infants, breastfeeding problems with, 503, 504f
Lateral fornix, 9f
Laxatives, 199, 199f, 204
LBW. See Low birth weight
Lead exposure, 56, 280, 282
Lederman, Regina, 297–301
LEEP (loop electrosurgical excision procedure), history of prior, 368
Legal and liability issues
fetal well-being assessment, 189–190
in management of pregestational obesity, 555–556
postnatal care, 438
Leg cramps, 205–206
assessment, 205
causes and symptoms, 205
relief and preventative measures, 205–206, 205f
Leg exam, postpartum, 434–435
Leg varicosities, 216–217
Leiomyoma
defined, 335
vaginal bleeding and, 337
Leopold’s maneuvers, 85, 125, 132–133, 134f, 362
Leptin, 5, 41
LES (lower esophageal sphincter), 203
Lesbian relationship
caring for the pregnant woman in, 304
legal issues, 305
psychosocial adaptation and attachment, 304–305
Let down reflex, 482–483
Leukocyte ALP, increase in pregnancy, 44
Leukonychia, 193
Leukorrhea, 205
assessment, 205
causes and symptoms, 205
defined, 193
as presumptive sign of pregnancy, 128
relief and preventative measures, 205
Levetiracetam, maternal and fetal effects of, 572f
Levonorgestrel
IUD, 467
oral, 474–475
Levothyroxine, 563, 566
LGA. See Large for gestational age
LH. See Luteinizing hormone
Libraries, as information source, 314
Life Course Perspective, 52
Lifestyle changes, for headache, 575
Lipid, increase during pregnancy, 41, 41f
Light therapy, for depression, 623
Lipolysis, 19, 25, 41
Lipolytic, 34
Liver and biliary adaptations of pregnancy, 40, 40f
LMP (last menstrual period), gestational age estimation, 137–138
LMWH (low-molecular-weight heparin), for thromboprophylaxis, 532, 533f
Lochia, 419–420
after stillbirth, 413
appearance of, 430f
defined, 423
flow, 430
postpartum, 430
in uterine infection, 444, 445f
Lochia alba, 420, 430
Lochia rubra, 420, 430
Lochia serosa, 420, 430
Long-acting reversible contraceptive methods (LARC), 462, 467–469
Loop electrosurgical excision procedure (LEEP), history of prior, 368
Loperamide, 545
Loratadine
for atopic dermatitis, 581
for pruritic urticarial papules and plaques of pregnancy (PUPP), 583
Lorazepam
FDA approved indications, 455f
side effects, 455f
Lordosis, 34, 45
Loss of control in labor, fear of, 300
Lotus birth, 23
Low birth weight (LBW) caffeine linked to, 111
defined, 352
link to coronary heart disease, 102–103
nutrition in pregnancy and, 100, 102–103
preconception care benefits and, 52
Lower esophageal sphincter (LES), 203
Lower UTI, defined, 356
Low milk supply, 499, 508–510, 508f–509f
Low-molecular-weight heparin
(LMWH), for thromboprophylaxis, 532, 533f
Lumbar lordosis, 193
Luteinizing hormone (LH), 13, 14f
newborn’s, 12
ovulation and, 15
puberty onset, 13
Lymphatic breast drainage therapy, 506
Lithium
for bipolar disorder, 626
teratogenicity of, 233f
Live birth, defined, 409
Live modeling experiences, 307

Macronutrients, 99
- dietary reference intakes, 106t
  - fats, 103–105
  - protein, 105
  - total energy, 103
Macrophages, 43–44
Macrosomia, 361–362
  - assessment and management, 362
  - defined, 352, 387, 397
  - in gestational diabetes, 388, 393
  - in post-term pregnancy, 404
Macrostomia, 361–362
Macroleukemias, 447
  - for preeclampsia, 447
  - for preclampsia management, 382
Magnesium supplements
  - for headache, 574
  - to reduce leg cramps, 206
Male partners
  - psychosocial adaptation and attachment, 303–304
  - sexuality in pregnancy, 284–285
Male sterilization (vasectomy), 473
Male genitalia, embryonic development of, 7f
Major depressive disorder (MDD), 621, 622t
Major histocompatibility complex (MHC), 43
Malathion, exposure to, 283
  - for pregnancy implications of use, 244
  - preconception counseling on, 60
  - prevalence of use, 244
Marital status trends in, 302t
  - prevalence of use, 244
Massage therapy
  - for depression, 623
  - for headache control, 575
Massively parallel shotgun sequencing (MPSS), 168
  - prevalence of use, 244
  - incidence of, 507
  - risk factors for, 507
  - signs and symptoms, 507
Material safety data sheets (MSDSs), 94, 280, 283
  - for pregnancy implications of use, 244
  - preconception counseling on, 60
  - incidence of, 507
  - risk factors for, 507
  - signs and symptoms, 507
Maternal attachment and adaptation, 292–301, 426–427
  - assessment of, 296
  - Bowlby and Ainsworth, 293
  - Brazelton, 294
  - detachment as protective mechanism, 299
  - Kennell and Klaus, 293–294
  - Lederman, 297–301
  - Rubin, 294–297
Maternal detachment as a protective mechanism, 299
  - for depression, 623
  - for headache, 574
  - for preeclampsia management, 382
  - in gestational diabetes, 388, 393
  - in post-term pregnancy, 404
  - in gestational diabetes, 388, 393
  - in post-term pregnancy, 404
  - defined, 352, 387, 397
  - assessment and management, 362
Medical and psychosocial interventions and follow-up, in prenatal care, 76
Medical eligibility criteria (MEC), 621, 622t
  - for MDD, 621, 622t
  - Mean corpuscular hemoglobin (MCH), 525–526, 526t
  - Mean corpuscular volume (MCV), 525–526, 526t
  - Meatus, 5
  - MEC (medical eligibility criteria), 462, 464–465
  - Meconium aspiration syndrome, 397
  - Meconium-stained amniotic fluid (MSAF), 356
  - Medicaid
    - Medicaid for Pregnant Women (MPW), 263
    - postpartum care visits, 463
    - Medical abortion, 144
    - Medical and psychosocial interventions and follow-up, in prenatal care, 76
    - Medical eligibility criteria (MEC), 462, 464–465
    - Medication(s), 223–236. See also specific drugs
      - breastfeeding mothers and, 493
      - case study, 236
      - controlled substances, 225, 226t
      - environmental exposure to pharmaceuticals, 224
      - government oversight of, 225, 226t
      - off-label prescribing, 225
      - pharmacokinetics and pregnancy, clinical implications of, 231, 234, 235t
Menarche, 5
  - average age for, 13, 15t
  - induction of, 13
Menopause, 621
Menstrual cycle physiology, 11–18
  - beginnings, 11–13
  - characteristics of normal cycle, 15t
  - endometrial cycle, 15–17, 17f
  - hormones of, 13, 14f, 15t
  - hypothalamic-pituitary-ovarian axis, 13
  - onset of puberty, 13
  - ovarian cycle, 13–15, 16f, 17f
Menstrual phase, of endometrial cycle, 16
Menstrual weeks. See Gestational weeks
Mental health. See also Psychological disorders
preconception care for illness, 64
preconception risk assessment and screening, 53, 56
prenatal care, 88
Menthol, for pruritic urticarial papules and plaques of pregnancy (PUPP), 583
Metabolites, 19, 21–22, 27–28, 27
Methadone
breastfeeding and, 254t
for opioid dependence, 248
Methamphetamine, pregnancy implications of use, 244
Methicillin-resistant Staphylococcus aureus (MRSA), 248
Methimazole, 564–565
Methotrexate, 343
Methylenedioxyprovalerone, 244
Methylergonovine
for delayed postpartum hemorrhage, 446
for subinvolution, 446
Methyleneethylmercury, 282
Methylyne, 244
Metoclopramide, for stimulation of milk production, 509
Metritis, 441, 443. See also Uterine infection
Metronidazole
for bacterial vaginosis (BV), 615
for trichomoniaisis, 614
MHC (major histocompatibility complex), 43
Micronutrients, 99
calcium, 106t, 107
folate, 106–107, 106t
iron, 105–106, 106t
vitamin D, 106t, 107
Midwives, history of, 75, 303
Mifepristone, 144
Migraine headache, 570, 574–576
Milk. See also Breastfeeding
defense agents in human, 482
expressing breast milk, 493–494
intake, assessing, 490–491
medication transfer into breast milk, 493
nutritional properties of human milk, 480–482
production of, 489, 490t
Milk supply, insufficient, 499, 508–510, 508r–509r
Milk thistle, for milk production stimulation, 510
Mimicry, 296
Mineralocorticoids, adrenal gland release of, 47
Minipills. See Progestin-only pills (POPs)
Misure, defined, 409
fear of, 284
Misoprostol, 144, 346
for antepartum fetal death, 410
teratogenicity of, 233r
Mittelschmerz, 5, 15
Modeling
live experiences, 307
symbolic, 307
Moderate preterm birth, 365–366
Modified biophysical profile, 187, 187f, 352, 361
defined, 352, 397
in post-term pregnancy, 406t
MoM (multiple of the median), 161, 168
Monounsaturated fatty acids (MUFAs), 99
Monozygotic twins, 397, 401
Mons pubis, 6, 6f
Montgomery’s tubercles/glands, 212, 483
Moody disorders
postpartum, 448–457
assessment and screening, 452
blues, 441, 449
management, 452–457, 453t–456t
signs and symptoms, 450t
prevalence of, 448
Moore method of fetal movement counts, 179
“Morning-after pill,” 474
Morning sickness, 207
Mortality, maternal. See also specific causes postnatal, 442, 442f
Morula, 19–20, 21f
Mother-daughter relationships, 298
“Mothering the mother,” 296
Motivational interviewing defined, 238
in substance use in pregnancy, 245
Motor vehicle accidents, 399
MPSS (massively parallel shotgun sequencing), 168
MRSA (methicillin-resistant Staphylococcus aureus), 248
MS (multiple sclerosis), 577
MSAF (meconium-stained amniotic fluid), 356
MSDs (material safety data sheets), 94, 280, 283
MSH (melanocyte-stimulating hormone), 42
Mucin, 5, 10
Mucolipidosis IV, genetic screening for, 167
MUFAs (monounsaturated fatty acids), 99
Multifetal pregnancy, 401–403
anticipatory guidance, 403
assessing fetal growth, 402
care of women with, 402
decreasing risk of preterm birth, 402
diagnosis of, 402
fetal surveillance, 402–403
incidence of, 401
nutritional counseling, 403, 403t
Multipara, defined, 325
Multiple of the median (MoM), 161, 168
Multiple sclerosis (MS), 577
Mupirocin, for cracked nipple infections, 45–46
Murphy’s sign, 544, 546
Muscle glycogen, 551
Musculoskeletal system, adaptations during pregnancy, 45–46
Myasthenia gravis, 44
Myometrium, 5, 9
Myometrial contractions, 45–46
Myometrium, 5, 9f, 10–11
MyPlate, 114, 115f
Naegele, Franz Karl, 73, 82
Naegele’s rule, 82, 137
Nail changes during pregnancy, 213
Nails, maternal alterations during pregnancy, 43
Narrow band ultraviolet B (NBUVB) phototherapy, for prurigo of pregnancy, 582
NAS. See Neonatal abstinence syndrome
Nasal congestion, 206
assessment, 206
causes and symptoms, 206
relief and preventative measures, 206
Nasal decongestant sprays, 206
National Diabetes Data Group (NDDG), 389, 389t
National High Blood Pressure Education Program Working Group (NHBPEP), 375, 380
National Institute of Child Health and Human Development (NICHD), 180
National Institute of Health (NIH), omega-3 intake recommendations of, 104
National Patient Safety Foundation, 316
National Quotilne Number, 91
National Society of Genetic Counselors (NSGC), 168
National Survey of Family Growth, 466–467
“Natural” childbirth, 299
Natural killer cells, 43–44
Nausea and vomiting of pregnancy (NVP), 207–209, 208t–209t, 209f
assessment, 207, 208t
case study, 218
causes and symptoms, 207
hyperemesis gravidarum (HG), 399–401, 400t
incidence of, 207
relief and preventative measures, 207–208, 208t–209t, 209f
NDDDG (National Diabetes Data Group), 389, 389t
NDRI. See Norepinephrine and dopamine reuptake inhibitor
Near-poverty, defined, 261
NEC (necrotizing enterocolitis), 502
Necrotizing enterocolitis (NEC), 502
Negative feedback, 13, 14f
Negative predictive value, 149, 176
Necrotizing enterocolitis (NEC), 502
Negative feedback, 13, 14f
Negative predictive value, 149, 176
Neisseria gonorrhoeae, 609–610
Neonatal abstinence syndrome (NAS), 252–253
assessment and treatment of, 252
breastfeeding and, 252
defined, 238
described, 252
long-term implications of, 252–253
Neonatal behaviors, maternal attachment and, 294
Neonatal death, defined, 409
Neonatal intensive care units, emotional disconnect for mothers and, 293
Neonatal withdrawal
benzodiazepines, 244
nicotine, 242
Nephrolithiasis, 536, 541
Nerve supply
to cervix, 10
to uterus, 11
to vagina, 8
Nervous system disorders (see Neurological disorders)
maternal alterations during pregnancy, 45
Neural crest cells, 28
Neural tube defects (NTDs) defined, 34
fetal deficiency and, 106
fetal for prevention of, 36
geneic screening test, 87t
preconception counseling on, 59
risk factors for, 162
screening options for, 161–162
Neurological disorders, 570–578
case study, 578
headache, 573–577, 574t–576t
multiple sclerosis (MS), 577
resources for women and their families, 578
seizure disorders, 570–573
terminology, 570
Neurontin, for bipolar disorder, 626
Neuropathic pain, 389, 389t
Nipple
See also Nipples
Nipples
defined, 434
Nipple sucking
See Breastfeeding
Nipple
See also Nipples
Assessment of, 112–114
Breastfeeding mother, 491–492
clinical trials, 112–114
factors influencing intake, 111–112
case study, 120–121
for breastfeeding mothers, 491–492
for optimal, 114, 116
in adolescent pregnancy, 111–117
clinical signs of nutritional status, 114t
history, 112, 112t–113t, 113f
resource use, 112, 114
resource availability, 111
factors influencing intake, 111–112
food and beverages, 106–107
for food safety, 109–111, 109f
food units, 100
needs in pregnancy
calcium, 106, 107
carbohydrates, 105
dietary reference intake, 106t
Noninvasive prenatal diagnosis (NIPD), 168–169
Noninvasive prenatal testing (NIPT), 168–169
Nonoxynol-9, 473
Nonrapid eye movement (NREM) sleep, 45
Nonsteroidal anti-inflammatory drugs (NSAIDs)
for afterbirth pain, 430
for headaches, 576
Nonstress test (NST), 180–183
defined, 352–353, 397
intrauterine growth restriction and
in post-term pregnancy, 406t, 407
Norepinephrine and dopamine reuptake inhibitor (NDRI)
black box warning, 455t
for depression, 457, 624t
FDA approved indications, 455t
side effects, 455t
Nosebleed, 206–207
Notochordal process, 19, 28, 29f
Nuchal translucency (NT) measurement, 160, 163–164
Nugent scoring system, 614–615, 615t
Nulliparous, 5, 325
Numerical risk, 154
Nutrition, 99–121
assessment of, 112–114
breastfeeding and, 252
clinical trials, 112–114
factors influencing intake, 111–112
case study, 120–121
for breastfeeding mothers, 491–492
for optimal, 114, 116
in adolescent pregnancy, 111–117
clinical signs of nutritional status, 114t
history, 112, 112t–113t, 113f
resource use, 112, 114
resource availability, 111
factors influencing intake, 111–112
case study, 120–121
for breastfeeding mothers, 491–492
food and beverages, 106–107
for food safety, 109–111, 109f
food units, 100
needs in pregnancy
calcium, 106, 107
carbohydrates, 105
dietary reference intake, 106t
Nutrition (cont’d)
fats, 103–105
fluid intake, 103
folate, 106–107, 106t
iron, 105–106, 106t
macronutrients, 103–105, 106t
micronutrients, 105–107, 106t
omega-3 fatty acids, 104–105
protein, 105
total energy, 103
vitamin D, 106t, 107
nutritional properties of human milk, 480–482
pica, 119–120
portion size, 100
postpartum, 429
poverty and, 262
prenatal, 90–91
health outcomes and, 100, 102–103
preterm birth prevention, 369–370
resources for health-care providers, 121
resources for women and their families, 121
serving size, 100, 101t
terminology, 99
for vegetarians and vegans, 117–118,
117t
weight gain, 107–108
Nutritional history, 84
Nutritional supplements, 224–225, 234
NVP. See Nausea and vomiting of pregnancy
Obesity, 549–558
assessment, 552–553
laboratory testing, 552
physical examination, 552–553
problem-focused health history, 552
case study, 557
comorbidities in pregnancy, 551
cultural considerations, 550
defined, 549
health disparities, 550
intrapartum issues, 556
management of pregestational, 552–556
assessment, 552–553
bariatric surgery, 555
comfort measures, 554
legal and liability issues, 555–556
nondiscriminatory language, 552
nutrition, 554
physical activity, 554
principles of, 553
scope of practice considerations, 555
weight loss, 554
personal and family considerations, 550
physiology, 551
postpartum issues, 556
potential problems associated with, 551–552, 552t
prevalence of, 108, 305, 550
resources for health-care providers, 556, 558
resources for women and their families, 556
risk factors for, 551
terminology, 549
Obesity Society, 552
Obesity Society, 552
Observe-compulsive disorder, postpartum, 450t, 451
Occupational exposures. See also Environmental exposures
Environmental and Occupational Health History Profile, 280, 281t
preconception risk assessment and screening, 56, 57f
preterm birth and, 367
Occupational Safety and Health Administration (OSHA), 94, 280
Office of Child Support Enforcement, 263
Off-labeling prescribing, 225
OLD CAARTS mnemonic, 398
Oligohydramnios, 23, 354–357
amniotic fluid index (AFI), 354–355, 356f
causes of, 356
defined, 19, 176, 353, 397
diagnostic assessment and management, 356–357
perinatal mortality rate (PMR), 354, 356
in post-term pregnancy, 404
preterm premature rupture of membranes (PPROM), 354–356
Omega-3 fatty acids, 99, 104–105
for mood and anxiety disorders, 457
perinatal outcomes and, 104
recommendations for intake in pregnancy, 104–105
in vegetarian/vegan diet, 118
Omega-6 fatty acids, 99, 118
Oocyte, 19, 20
Oogenesis, 5, 12, 12f
Oogonia, 5, 11–12, 12f, 19, 30
Open neural tube defects, 160
Opioids
breastfeeding and, 254t
dependence, psychiatric disorders comorbid with, 241
neonatal abstinence syndrome (NAS), 252–253
assessment and treatment of, 252
breastfeeding and, 252
described, 252
long-term implications of, 252–253
pregnancy implications of use, 243
replacement therapy, 249–251
breastfeeding and, 251
buprenorphine, 250–251
methadone, 250–251
Carpenter and Coustan criteria, 389, 389t
one-hour test, 389
three-hour test, 389, 389t
two-hour test, 389–390
Oral health, prenatal, 88
Oral rehydration therapy, for gastroenteritis, 545
Organic solvents, exposure to, 282
Organogeneration, 28–29
Organogenic, 19
Organophosphates, exposure to, 283
Os, 5
OSHA (Occupational Safety and Health Administration), 94, 280
OTC (over-the-counter) drug, 223–224
Otitis media, 522
Ovarian cycle, 13–15, 16f–17f
Ovarian ligament, 9f, 10–11
Ovary, 9f
anatomy, 11, 16
hypothalamic-pituitary-ovarian axis, 13, 14f
Over-the-counter (OTC) drug, 223–224
Overweight
defined, 549
prevalence of, 108, 305
Ovo-lacto vegetarians, 99, 117
Ovulation, 12–13, 15
after pregnancy loss, 340
first postpartum, 463
postnatal resumption of, 432
Oxcarbazepine, maternal and fetal effects of, 572f
Oxycodone, for restless leg syndrome, 210–211
Oxygen therapy, for headaches, 576f
Oxytocin
breastfeeding and, 430
defined, 325
for delayed postpartum hemorrhage, 446
for labor augmentation, 327
milk ejection reflex, 482–483
roles of, 46–47
Oxytocin challenge test (OCT), 183
Index
Physiological changes of pregnancy, 34–48
  cardiovascular changes, 37–38, 37t
  blood pressure, 37–38
  heart changes, 37, 37t
  supine hypotensive syndrome, 37–38
  vascular adaptations, 37
  case study, 47
  endocrine changes, 46–47
  adrenal function changes, 47
  anatomical changes, 46
  pituitary function changes, 46–47, 46t
  thyroid function changes, 47
  exercise and, 274–275
  gastrointestinal adaptations, 39–40
  exercise and, 274–275
  cardiovascular changes, 37–38, 37
  sebaceous and sweat gland changes, 42
  skin changes, 42–43
  connective tissue changes, 42
  pigmentation, 42
  sebaceous and sweat gland changes, 42
  skin changes, 42–43
  hematologic system adaptations, 34–36, 35t, 525–526
  clotting factors, 36, 36t
  folate requirements, 36
  iron requirements, 35–36
  plasma, 35
  red blood cells, 35
  white blood cells, 35
  immunologic changes, 43–45
  disorders related to, 44–45
  fetus as allograft, 43–44
  metabolic changes, 40–42
  basal metabolic rate, 41
  carbohydrate metabolism, 41
  fat metabolism, 41, 41t
  ghrelin, 41
  insulin, 41–42
  leptin, 41
  protein metabolism, 41
  musculoskeletal adaptations, 45–46
  nail changes, 43
  neurological changes, 45
  renal adaptations, 38–39
  anatomical changes, 39
  renal function, 39
  resources for health-care providers, 48
  resources for women and their families, 48
  respiratory adaptations, 38, 38t
  anatomical changes, 38
  pulmonary function adaptations, 38, 38t
  sensory changes, 45
  skin changes, 42
  connective tissue changes, 42
  pigmentation, 42
  sebaceous and sweat gland changes, 42
  vascular changes, 42
terminology, 34
thyroid physiology in pregnancy, 560–561, 561f
Physiology
  alterations during postnatal period, 419–422, 421t
  cardiovascular system, 421
  case study, 422
  cervix, 420
  endocrine changes, 421
  gastrointestinal tract, 421
  labia and perineum, 420
  lochia, 420
  renal system, 421
  resource for health-care providers, 422
  resource for women, 422
  uterus, 419–420
  vagina, 420
  of lactation and breastfeeding, 482–483
  obesity, 551
  of preterm birth (PTB), 366–367
  respiratory, 517
Phytoestrogens, 117
Pica, 19–120, 34, 527
Pigmentation
  changes during pregnancy, 42
  as presumptive sign of pregnancy, 128
  hyperpigmentation, 42, 212–213, 213f
Pinocytosis, 19, 23, 24t
Pitocin, for antepartum fetal death, 410
Pituitary gland, 13, 14f
  function changes during pregnancy, 46–47, 46t
  hormones, table of, 46t
  hypothalamic–pituitary-thyroid axis, 560, 561f
  size increase, 46
Placenta
  formation of, 21–22, 354, 355f
  functions, 23–25, 24t, 26t
  endocrine synthesis and secretion, 24–25, 26t
  transport, 23–24, 24t
  nutrition and, 102
  sociocultural uses of, 23
  structure of, 21–22
  transplacental infections, 24t
Placenta accreta, 20, 22
Placental abruption, 346–348
  case study, 349
  defined, 335, 346
  incidence of, 346
  potential problems, 347
  presentation, 347–348
  risk factors for, 347t
  types, 347, 347f
Placental encapsulation, 23
Placenta previa, 345–346, 346f, 346t
  defined, 335
  differential diagnosis, 346
  potential problems, 345–346
  presentation, 346
  risk factors for, 346t
  types, 345, 346f
Placentation
  defined, 34
  normal, 354
“Plant food,” 244
Plasma volume changes during pregnancy, 35
Platelet-derived growth factor, 34, 36
Platelet function activity, 531
Platelets, 34, 36
Plugged ducts, 506–507
PMSS (Pregnancy Mortality Surveillance System ), 442
Pneumonia, 522–523
Polycystic ovarian syndrome (PCOS)
  in gestational diabetes (GDM), 390
  metformin treatment, 392
Polyhydramnios, 22
  assessment and management, 357–358
  causes of, 357
  defined, 20, 176, 353, 357
Polymerase chain reaction (PCR)
  for CMV diagnosis, 591
  defined, 589
  for rubella virus diagnosis, 598
  for toxoplasmosis diagnosis, 600f, 601
  for varicella zoster diagnosis, 603–604
Polypathy, 223, 231, 234
Polyunsaturated fatty acids (PUFAs), 99
Polyzygotic gestation, 397, 401
Ponderal index, 353, 358
POP (progestin-only pills), 462, 471–472
Portion size, 99, 100
Position, for breastfeeding, 484, 487, 487f
Position statements on prenatal substance use, 240–241
Positive feedback, 13
Positive predictive value
  antenatal fetal testing, 177, 182
  defined, 149, 160, 176
Positive signs of pregnancy, 127t,
  132–133, 132f, 134f
  defined, 125
  fetal heart activity, 132, 132f
  fetal movement detection, 132–133, 134f
  ultrasound or X-ray detection, 132
Postbirth bonding. See also Attachment
  maternal pattern of behavior, 294
  prenatal preparation for, 294
Postconceptional weeks, 125
Postmortem examination, 409
Postnatal care
activity/exercise, 428–429
afterbirth pain, 430
assessment of maternal physical and
electrical balance in life, 425
family adaptation, 426–428
infant feeding, 428
maternal mood, 425–426
review of birth experience, 426
case study, 438
components of, 423–439
constipation, 431
contraception, 432–433
cultural considerations, 435–436
depression, 435
diaphragm, 431
diet and nutrition, 429
diuretics, 431
Postpartum anxiety disorders, 441
Postpartum blues, 423, 425–426, 441, 449
Postpartum complications
Postpartum blues, 423, 425–426, 441, 449
case study, 458
cultural considerations, 442–443
delayed postpartum hemorrhage, 441,
445–446
hematoma, 441, 446
mood and anxiety disorders, 441,
448–449, 448–457
assessment and screening, 452
blues, 423, 425–426, 441, 449
depression, 435, 449–450
generalized anxiety disorder (GAD),
451
incidence/prevalence of, 448
management, 452–457, 453–456
obsessive-compulsive disorder, 451
overview of, 448–449
panic disorder, 451
pathophysiology of, 449
post-traumatic stress disorder (PTSD),
451–452
psychosis, 451
risk factors for, 449
signs and symptoms, 450
morbidity and mortality, 442, 442f
postpartum hematoma, 446
preeclampsia/eclampsia, 441, 446–447
puerperal fever (pyrexia), 443
puerperal infection (postpartum
infection), 443–445
clinical presentation, 444, 445f
diagnosis and management,
444–445
maternal mortality from, 443
risk factors for, 444
uterine infection, 443–445,
444–445
resource for health-care providers,
458
resource for women and their families,
458
subinvolution, 441, 446
terminology, 441
thrombophlebitis, 447
thyroiditis, 447–448
wound infection, 445
abdominal, 445
perineal, 445
Postpartum depression, defined, 441.
See also Depression, postpartum
Postpartum Depression Screening Scale
(PDSS), 88, 452
Postpartum headache, 576
Postpartum hematoma, 441, 446
Postpartum infection
defined, 441
puerperal infection, 443–445,
444–445
wound infection, 445
Postpartum preeclampsia/eclampsia,
441, 446–447
Postpartum psychosis, 441, 448, 450f,
451
Postpartum thyroiditis (PPT), 447–448,
561, 565–566
Post-term pregnancy, 403–407
case study, 407
complications of, 404
defined, 397
incidence of, 403–404
management, 404–406
elective labor induction, 405
fetal surveillance, 405, 406f
labor-stimulating activities,
404–405
overview, 403–404
prevention, 404
risk factors for, 403–404
Post-traumatic stress disorder (PTSD)
childhood sexual abuse survivors, 268
comorbid with substance use, 241
postpartum, 450, 451–452
Potassium levels in pregnancy, 39
Pouch of Douglas, 9
Poverty, 262–264
defined, 261
homelessness and, 262–263
interdisciplinary care, 263
nutrition and, 262
thresholds by family size and number
of adults at home, 264
PP (prurigo of pregnancy), 581–582,
582f
PPROM (preterm premature rupture of
membranes), 354–356
PTT (postpartum thyroiditis), 447–448,
561, 565–566
PRAMS (Pregnancy Risk Assessment
Monitoring System), 436
Preconception care, 51–68
benefits of, 52
care for women with chronic diseases,
61–65, 63f
chronic hypertension, 61, 64
cancer survivors, 61
diabetes, 64
epilepsy, 64
HIV infection, 64
mental illness, 64
thyroid disorders, 64
case study, 67
challenges to providing, 51–52
content of, 53–66
defined, 51
disabilities and, 65
evidence supporting, 52, 53
for men, 65–66
counseling, 66
risk assessment and screening, 66
Preconception care (cont’d)
  national guidelines for, 53, 54f–55f
  preconception counseling, 57–61
  conception process, 60
  diet, 57, 59
  environmental exposure to toxins, 60–61
  exercise, 59
  infections, 60
  preparation for pregnancy and childbirth, 60
  substance use and abuse, 59–60
  supplementation, 59
  vaccinations, 61, 62t
  weight, 59
  with prior pregnancy history, 65
  with prior pregnancy loss, 65
resources
  consumer brochures for office setting, 68
  for health-care providers, 67–68
  tools for screening, 68
  for women and families, 66–67
  risk assessment and screening, 53–57
  and occupational exposures, 56, 57f
  genetics, 56
  history, 53
  infection, 56–57, 58t
  laboratory examination, 53
  medications, 56
  mental health issues, 53, 56
  physical examination, 53
  substance use and abuse, 53
  terminology, 51
Predictive value, 153
Predictione
  for impetigo herpetiformis (IH), 585
  for pemphigoid gestationis (PG), 584
Preeclampsia, 376–384
  atypical presentation, 382–383, 383t
  case study, 385
  criteria for diagnosis of, 377t
  defined, 570
  diagnostic evaluation of, 379–380
  blood pressure, 379
  edema and weight gain pattern, 379
  history, 379
  laboratory evaluation, 380, 381f
  physical examination, 380
  proteinuria, 379, 379t
  headache and, 574
  HELLP syndrome, 382
  immunologic component of, 44
  incidence of, 377
  interprofessional practice issues, 384
  long-term sequelae of, 383–384
management of, 380–382
  education, 382
  lifestyle recommendations, 380
  maternal and fetal surveillance, 380
  medication, 380, 382
  nutrition in pregnancy and, 100
  pathophysiology of, 377–378, 378f
  postpartum, 441, 446–447
  potential problems due to, 378
  prediction of, 383
  prevention of, 383
  risk factors for developing, 378–379
  risk management issues in office setting, 384
  seizures and, 571
  superimposed on chronic hypertension, 376f, 377
Pregestational diabetes, 566–567
  adverse pregnancy outcomes and, 567
  classifications, 566
  glycemic control, 567
  perinatal risks of, 567
  preconception counseling, 567
  Pregnancy-associated plasma protein-A (PAPP A), in genetic screening, 163
Pregnancy dating, 82, 248
  case study, 145
  counseling for, 140–145
  adoption counseling, 143–144
  after negative pregnancy test, 141
  after positive pregnancy test, 141
  delivery of test results, 140–141
  ethics and standards for reproductive options counseling, 142
  evidence-based information about pregnancy options, 143
  pregnancy termination, 144–145
  steps in pregnancy options counseling, 143
  for unintended pregnancy, 141–143
  early, 126
  resources for health-care providers, 145
  resources for women and their families, 145
  signs and symptoms of pregnancy, 127–133, 127f
  positive signs of pregnancy, 127f, 132–133, 132f, 134f
  fetal heart activity, 132, 132f
  fetal movement detection, 132–133, 134f
  ultrasound or X-ray detection, 132
  presumptive signs of pregnancy, 127–128, 127f
  amenorrhea, 128
  breast changes, 128
  subjective sensations, 128
  vaginal changes, 128
  probable signs of pregnancy, 127f, 128–132, 129f–130f
  basal body temperatures, 131
  cervical changes, 129
  endocrine pregnancy tests, 131–132
  enlargement of abdomen, 128–129
  palpation and ballottement of fetus, 130–131
  uterine changes, 129–130, 129f–130f
  vaginal changes, 129, 129f
  subjective symptoms, 127
  terminology, 125
Pregnancy Discrimination Act (PDA), 94
Pregnancy failures, 341
Pregnancy history, 82, 84
Pregnancy loss
  perinatal loss and grief, 409–415
  breaking the news, 410
  case study, 414
  cultural considerations, 412
  etiology of stillbirth, 410, 410t
  grieving and emotional care after loss, 411–412, 412t
  interconception care, 413
  physical care after stillbirth, 413
  postpartum follow-up, 413
  resources for health-care providers, 415
  resources for women and their families, 415
  rights of parents when a baby dies, 412t
  subsequent pregnancy care, 413–414
  terminology, 409
  rate with amniocentesis, 168
  rate with chorionic villus sampling, 168
Pregnancy Mortality Surveillance System (PMSS), 442
Pregnancy options counseling for unintended pregnancy, 141–145
  adoption, 143–144
  evidence-based information about, 143
  pregnancy termination, 144–145
  professional ethics and standards for, 142
  referral resources, 143
  steps in, 143
Pregnancy Risk Assessment Monitoring System (PRAMS), 436
Pregnancy termination counseling, 144–145
Pregnancy-Unique Quantification of Emesis (PUQE) Scale, 207, 208t
Prenatal care
amount of, 78–79
case study, 96
Centering Pregnancy model, 80–81, 81t
childbirth confidence enhancement, 306
components of, 81–95
diagnostic testing, 87–88
genetic screening, 86, 87t
goals, 73–77
health promotion and education, 88, 90–95
alcohol use, 92
exercise, 93–94
illicit drugs, 92–93
nutrition, 90–91, 91t
substance abuse, 91
throughout pregnancy, 94–95, 95t
tobacco use, 91–92, 92t
working and pregnancy, 94
history of, 74–75, 82, 83t, 84–85
integrating quality into, 79–80
laboratory studies, 85–86, 86t, 87t
nutrition counseling, 114, 116
physical assessment, 85
preventative care, 88–90
immunization, 88, 89f
intimate partner violence, 88, 90
mental health, 88
oral health, 88
resources for health-care providers, 97
resources for women and their families, 97
risk assessment, 81–82
structure of, 77–80
Prenatal diagnosis, 160
Prenatal education. See Health education
Prenatal flavor learning, 102–103
Prenatal preparation
for postbirth bonding, 294
teaching about fetal growth and development, 294
Prenatal screening, 160
Prenatal visit schedule, 78, 78t
Preparation for pregnancy and childbirth, preconception counseling, 60
Prepuce of clitoris, 6f
Prescription
components of, 225–226
sample, 227f
Prescription drugs, 223, 224
Prescriptive authority, 223–225
Presumptive signs of pregnancy, 127–128, 127t
amenorrhea, 128
breast changes, 128
defined, 125, 127
skin changes, 128
subjective sensations, 128
vaginal changes, 128
Preterm birth (PTB), 365–373
case study, 372
complications related to prematurity, 367, 367f
multifetal pregnancy, decreasing risk in, 402
nutrition in pregnancy and, 100
physiology of, 366–367
poor sleep quality as risk factor for, 214
predicting, 368
cervical length measurement, 368
fetal fibronectin (fFN) testing, 368
preeclampsia and, 378
preterm labor
diagnosis, 368
initial evaluation, 369
management of women with, 368–369
prevalence of, 365
prevention, 369–371
cervical cerclage, 371
fatigue reduction, 371
interpregnancy interval, 370
nutrition, 369–370
progesterone therapy, 371
sleep quality improvement, 371
smoking cessation, 370
treating infections, 370
resources for women and health-care providers, 373
risk factors for, 367–368, 367f
sexually transmitted infections (STIs) and, 608–609
social and racial disparities, 366
terminology, 365
Preterm birth rate, 365
Preterm infants, breastfeeding problems in, 502–503
Preterm labor. See also Preterm birth diagnosis, 368
initial evaluation, 369
management of women with, 368–369
Preterm premature rupture of membranes (PPROM), 354–356
Preventative care, prenatal, 88–90
immunization, 88, 89f
intimate partner violence, 88, 90
mental health, 88
oral health, 88
Primary follicles, 12f, 14–15
Primary oocytes, 11–12, 12f
Primidone, maternal and fetal effects of, 572f
Primipara, defined, 325
Primitive streak, 20, 27–28, 27f, 29f
Primogeniture, 302
Primordial follicles, 12f, 14
Prior pregnancy history, preconception care for women with, 65
Prior pregnancy loss, preconception care for women with, 65
Probable signs of pregnancy, 127t, 128–132, 129f–130f
basal body temperatures, 131
cervical changes, 129
defined, 125
diagnostic testing, 131–132
enlargement of abdomen, 128–129
enlargement of abdomen, 128–129
palpation and ballottement of fetus, 130–131
uterine changes, 129–130, 129f–130f
vaginal changes, 129, 129f
Probiotics, 545
Progestrone
appetite stimulation by, 40
carbonic anhydrase increase from, 38
corpus luteum secretion of, 15, 16–17
functions of, 25, 26f
gastrointestinal system changes during pregnancy, 40
gingivitis susceptibility and, 196
postpartum levels, 421
for preterm birth prevention, 371, 402
stimulation of cytochrome P450 enzymes, 40
tissue factor increase stimulated by, 36
varicosities and, 216
vasodilation effect of, 37–38
Progestin-only contraceptives, 462, 470–472
depot medroxyprogesterone acetate (DMPA), 470–471
implant contraception, 468–469
progesterin-only pills (POPs), 462, 471–472
Progestin-only pills (POPs), 462, 471–472
Progestins, in combined hormonal contraceptives (CHCs), 462, 464, 469–470
Projection, in maternal role taking, 296
Prolactin, 46, 483, 489
Proliferative phase, of endometrial cycle, 15–16
Propylthiouracil (PTU), 564–565
Prostaglandins
for cervical ripening, 406
defined, 325
for delayed postpartum hemorrhage, 446
labor and, 326
in menstrual phase of endometrial cycle, 17
vasodilation effect of, 37
Prostaglandin synthase inhibitor, 358
Protein
  in human milk, 481
  intake, 105, 106t
  metabolism changes during pregnancy, 41
  quality, 105
  in vegetarian/vegan diet, 118
Psychosis, postpartum, 441, 448, 450
Psychophysiology, 291
Psychological stress, of working during pregnancy, 105
Protozoa
  defined, 375
  in preclampsia, 379, 379t
Protomn (PT), 531, 532t
Protozoa
  defined, 589
  toxoplasmosis, 599–602, 600f, 601t
  Trichomonas vaginalis, 613–614
Prurigo of pregnancy (PP), 581–582, 582t
Pruritus gravidarum. See Intrahepatic cholestasis of pregnancy (ICP)
Psoriasis, 580
Pseudoephedrine, 206
PTSI (pancreatic secretory trypsin inhibitor), 480
Psychiatric medications causing weight gain, 551
Psychological disorders, 621–629
  bipolar disorder, 622t, 625–626, 626f
  case study, 628
  comorbid with substance use, 241
  depression during pregnancy, 621–625, 622t, 624t
  generalized anxiety disorder (GAD), 626–627
  mood disorders, definition and classification of, 622t
  prevalence of, 621
  resources for health-care providers, 629
  resources for women and their families, 629
  scope of practice considerations, 627–628
  terminology, 621
Psychological stress, of working during pregnancy, 287
Psychophysiology, 291
Psychosis, postpartum, 441, 448, 450t, 451
Psychosocial adaptations in pregnancy, 291–309
  body image, 305–306
  case study, 309
  childbirth confidence, 306–308
  dimensions of (Lederman’s)
    acceptance of pregnancy, 297
    fear of loss of control in labor, 300
    fear of loss of self-esteem in labor, 301
    identification with a motherhood role, 297–298
    preparation for labor, 299–300
  relationship with own mother, 298
  relationship with partner, 298–299
  maternal attachment and adaptation, 292–301
  assessment of, 296
  Bowlby and Ainsworth, 293
  Brazelton, 294
  detachment as protective mechanism, 299
  Kennell and Klaus, 293–294
  Lederman, 297–301
  Rubin, 294–297
  partner adaptation and attachment, 302–305, 302t
  assessment of, 303
  lesbian partners, 304–305
  male partners, 303–304
  pregnancy as crisis, 292–293
  pregnancy as developmental phase, 292–293
  resources for health-care providers, 309
  resources for women and their families, 308
  sibling adaptation and attachment, 301–302
  terminology, 291
  Psychosocial assessment, of pregnant women with substance use disorders, 248
  Psychosocial benefits of exercise, 275
  Psychosocial effects in genetic testing, 348
  Psychosocial history, 84
  Psychosocial impacts of sexually transmitted infection diagnosis, 616–618
  effects on the individual, 616–617
  preventing STIs within relationships, 617–618
  Psychotherapy. See also Cognitive-behavioral therapy (CBT)
    for depression, 623
    for generalized anxiety disorder, 451
    interpersonal (IPT), 452, 457
    for mood and anxiety disorders, 457
    for panic disorder, 451
    for postpartum depression, 450
    for post-traumatic stress disorder, 452
  Psychotropics
    defined, 441
    for panic disorder, 451
    PT (prothrombin time), 531, 532t
  PTH. See Preterm birth
  PTSD. See Post-traumatic stress disorder
  PT (partial thromboplastin time), 531, 532t
  PTU (propylthiouracil), 564–565
  Pylalism, 209–210
  assessment, 210
  causes and symptoms, 209
  defined, 193, 209
  in hyperemesis gravidarum, 400
  relief and preventative measures, 210
  Puberty
    follicles present at, 11
    onset of, 13
  Pubic hair, 6
  Pubic symphysis, 8f
  Pubococcygeus muscles, 8
  PUBS (percutaneous umbilical blood sampling), 168
  Pudendal nerve, 8
  Puerperal fever (pyrexia), 443
  Puerperal infection (postpartum infection), 443–445
    clinical presentation, 444, 445t
    diagnosis and management, 444–445
    maternal mortality from, 443
    risk factors for, 444
    uterine infection, 443–445, 444t–445t
  Puerperium, 423, 441
  PUFAs (polyunsaturated fatty acids), 99
  Pulmonary embolism, 531–532
  Pulmonary function adaptations during pregnancy, 38, 38t
  Pulmonary function testing, 518
  Pulmonary hypoplasia, 20, 23
  PUQE (Pregnancy-Unique Quantification of Emesis) Scale, 207, 208t
  Pruritic folliculitis of pregnancy (PFP), 582t, 583
  Pruritic urticarial papules and plaques of pregnancy (PUPP), 582–583, 582f, 582t, 587
  Purpura, 213
  Pyelonephritis, 536, 538, 540–541
  Pyrexia (puerperal fever), 443
  Pyrimethamine, for toxoplasmosis, 601
  Pyrosis. See Heartburn
  Pytalism, 34, 40
  Pyuria, 536, 541
  Quad screen, 161, 163–164, 163t
  Quality, integrating into prenatal care, 79–80
  Quickening
    defined, 20, 30, 125
    timing of, 128
  A Quick Reference Guide to Contraception, 475
  RAAS (renin-angiotensin-aldosterone system), 35, 39
  Racial disparities
    in preterm birth rates, 366
    risk of prenatal death, 189
  Randomized clinical trials (RCTs), 229
  Ranitidine, 203
  Rapid eye movement (REM) sleep, 45
onset of puberty, 13
ovarian cycle, 13–15, 16f, 17f
oogenesis, 12, 12f
resources for health-care providers, 18
resources for women, 18
terminology, 5
Requirement, 99
Reservoir, defined, 589
Residual volume, 517
Resorption, bone, 34, 45
Respiratory disorders, 517–523
asthma, 517–521, 519f, 520f
case study, 523
influenza, 521, 523
pneumonia, 522–523
resources for health-care providers, 523
terminology, 517
upper respiratory infection, 521–522, 522f
Respiratory system
adaptations during pregnancy, 38, 38f
anatomical changes, 38
pulmonary function adaptations, 38, 38f
shortness of breath, 211–212
Rest
early labor and, 329–330
for preeclampsia management, 380
assessment, 210
causes and symptoms, 210
relief and preventative measures, 210–211
Retinoids, teratogenicity of, 233f
Rh antigen, 74
Rh incompatibility, 44–45
Rhinitis, 206
RhoGAM, 74, 340
Riboflavin supplements, for headache, 574
Rising, Sharon Schindler, 73
Risk, 149–157
absolute, 149, 153
attributable, 149, 153
background, 223, 228
benefits of assessment, 150
case study, 157
defined, 149
disadvantages of assessment and management, 150–151
illusion of risk control, 151
labeling women as “high risk,” 151
normalization of technology, 151
unnecessary interventions, 150–151
of drugs during pregnancy, 226–227
explaining to women, 153–154, 155f, 156f
genetic disorders, 160–161
of genetic screening tests, 161
informed consent, 154–157
limitations of assessment, 150
lack of precision, 150
nonmodifiable risk factors, 150
poor predictive value, 150
misapplication of assessment and management, 151–153
birth fear, 153
cost increase, 152–153
introduction of actual risk, 152
miscommunication, 154
illusion of choice, 154
informed compliance, 154
perspective of risk and risk screening, 153
preventions, primary and secondary, 153
process and purpose of assessment, 149–150
relative, 149, 153
terminology, 149
Resources for health-care providers and women and their families, 157
Risk assessment
in prenatal care, 76
prenatal care and, 81–82
Risk factors
defined, 51, 149
for infections in pregnancy, 58f
nonmodifiable, 150
for preterm birth (PTB), 367–368, 367f
Risk scoring tools, 150
Ritual
baby shower as, 299
fatherhood, 303
functions of, 299
RLS. See Restless leg syndrome
Role
conflicts, 298
defined, 291
fatherhood, 303–304
identification with motherhood, 297–298
Role playing, 296
Round ligament pain, 211, 211f, 398f
assessment, 211
causes and symptoms, 211
relief and preventative measures, 211
Round ligaments, 10
Roux-en-Y gastric bypass, 549, 555
RPE (rating of perceived exertion), 277, 277f
Rubella, 227, 597–599
congenital rubella syndrome (CRS), 227, 598–599
management, 597–599
presentation and assessment, 598
prevention, 599
Rubin, Reva, 294–297
Rugae, 5, 8, 9f
Saccharin, 111
Sacral nerve, 8
Sacroccygeal teratoma, 20, 28
Sacral sacroiliac joint pain, 194
Sadovski method of fetal movement counts (FMCs), 179
Safety issues, discussing, 317
Salivation, excessive. See Ptyalism
Saturated fats, 117
Saturated fatty acids, 99
Schedule of prenatal visits, 78, 78t
Schedules for controlled substances, 225, 226t
Sciatica, 194
SCJ (squamocolumnar junction), 5
SCOFF tool to screen for eating disorders, 119
Screening, defined, 51
Seafood consumption, 104–105, 105t
Sebaceous gland changes during pregnancy, 42
Secobarbital, 329
Secondary oocyte, 12, 12f
Secondary sexual characteristics, 13
Second-degree laceration, 423
Secondhand smoke, 494
Secondhand smoke, 494
Secondary sexual characteristics, 13
Secretory phase, of endometrial cycle, 16
Secretory IgA, in colostrum, 480
Secondary sexual characteristics, 13
Seafood consumption, 104–105, 105t
Screening, defined, 51
Secondary sexual characteristics, 13
Secretory phase, of endometrial cycle, 16
Seizure disorders, 570–573
Self-care in early labor, 329
Self-efficacy
childbirth and, 306–308
defined, 291
influence of witnessing a birth on, 300
sources of information affecting beliefs, 306–307
performance accomplishment, 307
verbal persuasion, 307
vicarious experience, 307
visceral arousal, 307
strategies to enhance, 308
Self-esteem
defined, 291
fear of loss in labor, 301
Self-image
of male partners, 304
as mother, 298
Seminalgograft, 34
Sensitivity, 153
antenatal fetal testing, 177
defined, 149, 160, 176
Sensory changes during pregnancy, 45
Seroconversion, defined, 589
Seroprevalence, defined, 589
Serotonin discontinuation syndrome, 457
Serotonin norepinephrine reuptake inhibitors (SNRIs)
black box warning, 454t
for depression, 624, 624t
FDA approved indications, 454t–455t
for generalized anxiety disorder (GAD), 627
mechanism of action, 457
tside effects, 454t–455t
Sertaline
drug-drug interactions and, 248
FDA approved indications, 454t
side effects, 454t
Serving size, 99
defined, 100
guidelines and needs in pregnancy, 101t
Sexual health, 84, 285
Sexuality
defined, 291
postpartum, 431–432, 463
in pregnancy, 284–286
adaptations, 303–304
contraindications to intercourse, 285
counseling, 285–286
pregnancy influences on sexuality, 284–285
sexual health, 285
types of sexual activity, 285
Sexually transmitted infections (STIs), 608–619
case study, 619
chlamydia, 609
discussing diagnosis, 617
gonorrhea, 609–610
herpes simplex virus (HSV), 610–612, 611t–612t
human papillomavirus (HPV), 612–613
partner treatment, 616
preconception screening, 53
preventing, 617–618
psychosocial impacts of diagnosis, 616–618
effects on the individual, 616–617
preventing STIs within relationships, 617–618
reportable diseases, 608, 616
resources for health-care providers, 619
resources for women and partners, 619
syphilis, 610
termiology, 608
Trichomonas vaginalis, 613–614
SGA (small for gestational age), 353, 358–360
Sheppard-Towner Maternity and Infancy Protection Act, 73–74
Shift work, 274, 286
Shingles. See Varicella zoster virus (VZV)
Shortness of breath, 211–212
assessment, 211–212
causes and symptoms, 211
relief and preventative measures, 212
Shoulder dystocia, in gestational diabetes, 388, 393
SHS. See Supine hypotension syndrome
Siblings
adaptation and attachment, 301–302
postnatal adjustment by, 427–428
Sick cell disease, 525, 529
tnestic screening for, 87t, 165, 166t, 167
Sickle cell trait, 525, 529
SickleDex test, 167
Side effect, defined, 223
SIDS (sudden infant death syndrome), 242
Simethicone, 202
Simple diffusion, 20, 23, 24t
Sinusitis, 522
Sitz baths, for perineal discomfort, 431
Skin
changes, 212–214
assessment, 213
hair and nail changes, 213
hyperpigmentation, 212–213, 212f
presumptive signs of pregnancy, 128
relief and preventative measures, 213–214
striae gravidarum, 212–213, 213f
vascular changes, 213
disorders (see Dermatological disorders)
maternal alterations during pregnancy, 42
connective tissue changes, 42
pigmentation, 42
sebaceous and sweat gland changes, 42
vascular changes, 42
Skin tags, 42, 213
Sleep
changing patterns during pregnancy, 45
eye labor and, 329–330
for obese women during pregnancy, 554
quality improvement for preterm birth prevention, 371
recommended amount of, 287
Sleep disturbances, 214–215
assessment, 214
case study, 219
causes and symptoms, 214
relief and preventative measures, 214–215
workplace fatigue and, 287
Sleep hygiene, 193
Sleepy baby, breastfeeding problems and, 500–501
Slow weight gain, in breastfed infant, 501–502
SMA.
Slow weight gain, in breastfed infant, 501–502
SMA.
Slow weight gain, in breastfed infant, 501–502
SMA.
Slow weight gain, in breastfed infant, 501–502
SMA.
Slow weight gain, in breastfed infant, 501–502
SMA.
Slow weight gain, in breastfed infant, 501–502
SMA.
Slow weight gain, in breastfed infant, 501–502
SMA.
Slow weight gain, in breastfed infant, 501–502
SMA.
Slow weight gain, in breastfed infant, 501–502
SMA.
Slow weight gain, in breastfed infant, 501–502
SMA.
Slow weight gain, in breastfed infant, 501–502
SMA.
Slow weight gain, in breastfed infant, 501–502
SMA.
Slow weight gain, in breastfed infant, 501–502
SMA.
position statements on, 240–241
postpartum care, 253–254
preconception counseling on, 59–60
preconception risk assessment and screening, 53
prenatal health promotion and education, 91–93
prevalence of prenatal, 239
resources for health-care providers, 256
resources for women and their families, 256
risks of perinatal, 238–239
scope of practice considerations, 254
screening for prenatal substance abuse, 244–245, 245t
terminology, 238–240
Sudden infant death syndrome (SIDS), 242
Suicide, 450
substance abuse and, 239
Sulfadiazine, for toxoplasmosis, 601
Sulfamethoxazole/trimethoprim, for Listeriosis, 545
Superficial muscles of the perineum, 8, 8f
Superficial transverse perineal muscle, 8, 8f
Supernatural venous thrombosis defined, 441
postpartum, 447
Supine hypotension syndrome (SHS), 37–38, 215
assessment, 215
causes and symptoms, 215
relied and preventative measures, 215
Supplemental Nutrition Assistance Program (SNAP), 550
Supplements calcium, 383
folic acid/folate, 59, 141, 162, 211, 224, 530
iron, 106, 527, 527t
magnesium, 206, 574
for mood and anxiety disorders, 457
nutritional, 224–225, 225t
omega-3, 104
preconception counseling on, 59
for preclampsia prevention, 383
riboflavin, 574
thiamine, 401
Supplies for the baby, gathering of, 299
Support stockings, 447
Suspensory ligament, 9f
Swallowing by breastfeeding infant, 483
Sweat gland changes during pregnancy, 42
Sweeteners, alternative, 111
Symbolic modeling experiences, 307
Symphysis-fundus measurements, 138
Symphysis pubis diastasis, 195, 195f
Symphyisis separation, 195, 195f
Symptom review, mnemonic for, 194
Syncytiotrophoblast, 20–21, 24–25
Syphilis, 608
congenital, 610
neonatal, 610
pregnancy testing and treatment, 610, 610t
screening recommendations, 58t
signs and symptoms, 610
T-ACE Screening Tool for Alcohol Use, 92, 245t
“Talk test,” 278
Tannins, 106
Targeted ultrasound, 353, 356, 360
Target lesion, 580, 583
Tay-Sachs disease, genetic screening for, 205, 165, 166t, 167
TBG (thyroxine-binding globulin), 47
tCAs. See Tricyclic antidepressants
T-cytotoxic cells, 44
Technology dependency, 306
Teen pregnancy. See Adolescents
Telangiectasia, 34
Telephone triage tool for neonates, 486f
Telogen, 34, 43
Tension headache, 570, 574, 575t
Tentative pregnancy, 171
Teratogen, 28
alcohol as, 242
defined, 20, 223, 589
Teratology, 227–231
critical periods in human development, 228–229, 230t
drugs with minimal or no teratogenicity, 234t
etiology of birth defects, 228, 228f
examples of teratogens, 232r–233r
FDA categories for drugs in pregnancy, 229, 231, 231t
history of, 227
identification of a teratogen, 229
mechanisms of teratogenic drugs, 228–229
Wilson’s six principles of teratology, 228, 228t, 229
Testosterone, adrenal, 47
Tetracyclines, teratogenicity of, 233t
Thalassemia, 525, 527t, 529–530
genetic screening for, 87t, 165, 166t, 167
Thalidomide, 75, 227, 233t
Thelarche, 5
T-helper cells, 44
Therapeutic rest, 325, 330
Therapeutic window, 223
Thiamine supplementation, for Subchorionic hemorrhage, 335, 337
Thiamine supplementation, for pregnancy, 37
Thalassemia, 525, 527

The following are summary captions for the index entries:

**Symphyisis Separation**: 195, 195f
- Symphyisis separation is discussed in the context of pain management and is associated with postpartum care.
- It is also related to symptoms of pregnancy and neonatal care.

**Symphysis Fundus Measurements**: 138
- Symphysis-fundus measurements are used in prenatal health promotion and education.
- They are critical for assessing fetal health and are related to educational and screening tools.

**Symphysis Pubis Diastasis**: 195, 195f
- Symphysis pubis diastasis is a condition affecting women during pregnancy and is related to posture and movement.
- It is also associated with antepartum assessment and screening.

**Symphysis Separation**: 195, 195f
- Similar to the above, this entry highlights the condition’s relation to pain and its management.

**Supernatural Venous Thrombosis**: 441
- Supernatural venous thrombosis is defined in the context of antenatal care.
- It is related to pregnancy and related complications.

**Symphyisis Separation**: 195, 195f
- This entry combines the references from Symphyisis separation and Symphysis fundus measurements, emphasizing their importance in prenatal care.

**Symphysis Pubis Diastasis**: 195, 195f
- This entry might overlap with the previous entries, focusing on the diastasis’s role in antepartum care.

**Symphyisis Separation**: 195, 195f
- This entry again highlights the condition’s significance in prenatal and neonatal care.

**Symphyisis Separation**: 195, 195f
- Lastly, this entry provides a comprehensive look at the condition’s relevance across different aspects of prenatal care.

In summary, the index provides a detailed map of topics related to prenatal and neonatal care, emphasizing conditions and their management.
Thrombocytes. See Platelets
Thrombocytopenia, 531
  defined, 375
  in preeclampsia, 381
Thromboembolic disorders, 531–534
Thrombophlebitis
  postpartum, 447
  as sequela to IV drug use, 241
Thromboprophylaxis, 532–534, 533
Thrombolysis, 34, 53
Thromboxane, 34, 36
Thromboprophylaxis, 532–534, 533
Thrombophilia, 525, 531–534
Thromboembolic disorders, 531–534
Thrombocytopenia, 531
  postpartum, 447–448, 561
  defined, 441
Hypothalmic-pituitary-thyroid axis,
  function changes during pregnancy, 47
Thyroid physiology in pregnancy,
  thyroid hormone fluctuations
  size increase, 46
Thyroid disorders, 560–566
  causes and expected laboratory findings, 561
  diagnosing, 561–562
  hyperthyroidism, 561t, 564–565
  clinical presentation, 564
  diagnosis, 564
  Graves’ disease, 561t, 564
  laboratory testing, 561t, 564
  management, 564–565
  maternal and fetal risks, 564
  scope of practice considerations, 565
  signs and symptoms, 562
  subclinical, 561t, 565
  thyroid storm, 561t, 565
  hypothyroidism, 561t, 562–564
  clinical presentation, 562
  complications of, 562
  diagnosis, 562–563
  Hashimoto’s thyroiditis, 561t,
  562–563
  laboratory testing, 561t, 562–563
  management, 562–563
  maternal and fetal risks, 562
  overt, 562–563
  preconception care, 564
  screening in pregnancy, 563–564
  signs and symptoms, 562
  subclinical, 561t, 563
  postpartum thyroiditis (PPT),
  447–448, 561t, 565–566
  preconception care, 64
  signs and symptoms, 562
  thyroid physiology in pregnancy,
  560–561, 561f
Thyroidecby, 564
Thyroid gland
  function changes during pregnancy, 47
  hypothalamic-pituitary-thyroid axis,
  560, 561f
  size increase, 46
  thyroid hormone fluctuations
  throughout pregnancy, 561f
Thyroid hormones, 47, 560–565, 561f,
  561t
Thyroiditis
  defined, 441
  postpartum, 447–448, 561t, 565–566
Thyroidecby, 564
Thyroid-releasing hormone (TRH), 560,
  561f
Thyroid-stimulating hormone (TSH),
  46, 47, 560–565, 561f, 561t
Thyroid-stimulating immunoglobulins
  (TSIs), 564
Thyroid storm, 441, 560, 561t
Thyrotoxicosis (thyroid storm),
  441, 560, 561t
Thyroxine-binding globulin (TBG),
  47
Thyroid-stimulating hormone (TSH),
  560, 561t
Thyroid-stimulating immunoglobulins
  (TSIs), 564
Thyroid-releasing hormone (TRH), 560,
  561t
Thyroid storm, 441, 560, 561
Thyrotoxicosis (thyroid storm), 441, 560,
  561t
Thyroxine-binding globulin (TBG), 47
Tiagabine, maternal and fetal effects of,
  572
Tindazole, for trichomoniasis, 614
Toxoplasma gondii.
  Toxoplasmosis
  Screening options for, 162–165, 163
  defined, 160
  features of, 162
  genetic screening test, 87t
  incidence of, 162
  screening for, 162–165, 163t
Trisomy 18, 162
  defined, 160
  features of, 162
  genetic screening test, 87t
  incidence of, 162
  risk factors for, 162
  screening options for, 162–165, 163t
Trophoblast, 354
TSH. See Thyroid-stimulating hormone
TSIs (thyroid-stimulating immunoglobulins), 564
TTC SOC (transtheoretical stages of change), 274, 276–277, 276t
Tubal pregnancy, chlamydia and, 609
Tubal sterilization, 466
Tuberculosis, screening
  recommendations, 58t
  TULs (tolerable upper intake levels), 99
Tumor necrosis factor alpha (TNFα), 551
TWEAK screening tool, 245
Twins. See Multifetal pregnancy
TwoDay Method, of fertility awareness, 479
Type 1 diabetes, 560, 566, 566t
Type 2 diabetes, 560, 566
UFH (unfractionated heparin), for
  thromboprophylaxis, 532, 533t
Ulipristal acetate, 474–475
Venous ultrasonography, 447
Venous thrombosis, 433
Venous thromboembolism (VTE), 433
Venous thrombosis. See also Deep vein thrombosis (DVT)
Venouls ultrasonography, 447
Ventilation and perfusion (V/Q) scan, for pulmonary embolism, 532
Verbal persuasion, as self-efficacy information source, 307
Vertebral compression fracture, 307
Vertical transmission, defined, 589
Very preterm birth, 365–366
Very small for gestational age (VSGA), 358, 360
Vesicouterine pouch, 5, 9
Vesicovaginal septum, 5, 9
Vestibule, 5–6, 7f, 8
Vibroacoustic stimulation (VAS), 182
Vicarious experience, as self-efficacy information source, 307
Violence. See Intimate partner violence
Viral disease. See also specific viruses
cytomegalovirus (CMV), 590–591
ehpaititis A virus (HAV), 593–594
ehpaititis B virus (HBV), 594–596
ehpaititis C virus (HCV), 596–597
influenza, 521, 523
parvovirus B19, 597
rubella, 597–599
sexually transmitted infections (STIs), 610–613
upper respiratory infection, 521–522, 522f
varicella zoster virus (VZV), 602–603
Viseral arousal, as self-efficacy information source, 307
Visual changes, 219–220
assessment, 219
causes and symptoms, 219
relief and preventative measures, 220
Vitamin B12 deficiency and anemia, 527, 530
hematological findings during normal pregnancy, 526f
Vitamin D, 46
dietary intake during pregnancy, 106f, 107
in human milk, 481
in vegetarian/vegan diet, 118
Vitamins, in human milk, 481
Voiding by breastfed infants, 490–491
Vomiting
hyperemesis gravidarum (HG), 399–401, 400f
nausea and vomiting of pregnancy (NVP), 207–209, 208f–209f, 209f
von Willebrand’s disease, 531
defined, 441
delayed postpartum hemorrhage and, 446
VSGA (very small for gestational age), 358, 360
VTE (venous thromboembolism), 433
Vulnerable populations, postnatal care in, 436–437
Vulva, 5–6, 6f
Vulvar varicosities, 217–218, 217f
VZV. See Varicella zoster virus
Waist circumference, 549
Walking, 277
in obese women during pregnancy, 554
postpartum, 429
Warfarin, 532
Warmth, increased, 204–205
Warning signs, postnatal, 435, 435f
Water consumption, strategies to increase, 103
Water content of human milk, 480
Weight, preconception counseling on, 59
Weight gain, 107–108. See also Obesity advice for achieving healthy, 108
body image and, 305–306
by breastfed infants, 491
distribution of, 107
from fluid retention in pregnancy, 39
in gestational diabetes (GDM) management, 391
IOM recommended pregnancy, 90, 91f
overweight and obesity in pregnancy, 108
pattern in preeclampsia, 379
psychiatric medications causing, 551
recommendations for, 107–108, 108f
underweight in pregnancy, 108
Weight loss
with hyperemesis gravidarum, 399
in obese women during pregnancy, 554
postpartum, 429–430, 491
Wernicke’s encephalopathy defined, 397
in hyperemesis gravidarum, 400
Wharton’s jelly, 20, 23
White blood cells, changes during pregnancy, 35
WHO. See World Health Organization
Wilson, Jim, 228–229
Witch hazel, for perineal discomfort, 431
Withdrawal
benzodiazepines, 244, 627
opioid, 249–252
Withdrawal, method of contraception, 474
Witnessing birth, 300
Women, Infants, and Children (WIC) nutrition program, 90, 114, 262, 550
<table>
<thead>
<tr>
<th>Term</th>
<th>Page(s)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Working during pregnancy</td>
<td>94, 286–288</td>
</tr>
<tr>
<td>data gathering and counseling</td>
<td>287–288</td>
</tr>
<tr>
<td>discrimination</td>
<td>287</td>
</tr>
<tr>
<td>heavy lifting</td>
<td>286</td>
</tr>
<tr>
<td>long hours</td>
<td>286–287</td>
</tr>
<tr>
<td>noise exposure</td>
<td>287</td>
</tr>
<tr>
<td>psychological stress</td>
<td>287</td>
</tr>
<tr>
<td>resource on work during pregnancy</td>
<td>288</td>
</tr>
<tr>
<td>for women</td>
<td>288</td>
</tr>
<tr>
<td>shift work</td>
<td>286</td>
</tr>
<tr>
<td>Workplace, nursing mothers in</td>
<td>493–494</td>
</tr>
<tr>
<td>World Health Organization (WHO)</td>
<td></td>
</tr>
<tr>
<td>Baby-Friendly Hospital Initiative (BFHI)</td>
<td>480</td>
</tr>
<tr>
<td>growth charts</td>
<td>491</td>
</tr>
<tr>
<td>medical eligibility criteria (MEC)</td>
<td>464, 471</td>
</tr>
<tr>
<td>preterm birth, report on</td>
<td>365</td>
</tr>
<tr>
<td>Wound infection, postpartum</td>
<td>445</td>
</tr>
<tr>
<td>abdominal</td>
<td>445</td>
</tr>
<tr>
<td>perineal</td>
<td>445</td>
</tr>
<tr>
<td>Z-linked conditions</td>
<td>167</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Term</th>
<th>Page(s)</th>
</tr>
</thead>
<tbody>
<tr>
<td>X-ray, pregnancy diagnosis by</td>
<td>132</td>
</tr>
<tr>
<td>Yolk sac</td>
<td>22</td>
</tr>
<tr>
<td>Zolpidem</td>
<td>329</td>
</tr>
<tr>
<td>Zona pellucida</td>
<td>5, 14–15, 20</td>
</tr>
<tr>
<td>Zonisamide, maternal and fetal effects</td>
<td>572t</td>
</tr>
<tr>
<td>Zung Self-Rating Anxiety Scale</td>
<td></td>
</tr>
<tr>
<td>Hamilton Anxiety Rating Scale</td>
<td>627</td>
</tr>
<tr>
<td>Zygote</td>
<td>20</td>
</tr>
</tbody>
</table>